>
Vital Signs : Indian Digital Health Outlook
Volge
Quarterly
Q4 2025 · The Indian Digital Health issue
Sovereign Stack
Who owns the Gulf stack
AI Rollouts
Fleets, run like production
Licence
The audit-letter economy

Vital
Signs

India's health system goes digital: 700 million ABDM identities, AI in the district hospital, and the DPDP reckoning ahead.

volge.com/quarterlyComplimentary editionISSN 2977-4404 · 07

Volge Quarterly is Volge's signature series, published every quarter for enterprise customers. Each edition takes one subject, sets out where it currently stands on the published record, and makes a set of dated, falsifiable judgements on where it is going, written to give a buyer something firmer than a forecast: every figure carries its source and its date, every judgement carries the date on which it resolves, and the following year's edition grades each one hit, missed or partial.

The market stops paying for growth and starts paying for unit economics. Who survives the reckoning of 2027, and where the value moves next.

Figures carry their basis and their date. Where published estimates disagree, the range is given and the basis named rather than averaged away, and where a widely quoted number does not survive checking it is corrected here rather than repeated. Every chart plots a figure stated in the text, and nothing is projected beyond what a named source projects.

Contents

  1. 02The year the market starts paying for unit economics
  2. 02The state of the sector
  3. 02The sector in numbers
  4. 03Where the sector stands
  5. 03India versus the world: three models
  6. 04Why India, why now
  7. 04The seven segments
  8. 04The segments in depth
  9. 05The segments in depth: the profiles
  10. 06The public rails: ABDM and eSanjeevani
  11. 06Market economics: the unit-economics test
  12. 07The payer problem, and the escape route
  13. 07Regulation: a patchwork still settling
  14. 08The competitive landscape
  15. 08The funding anatomy
  16. 08Generative AI across the sector
  17. 09The underserved verticals
  18. 09The global backdrop
  19. 10Building on the rails: the health stack
  20. 10Teleconsultation & telemedicine
  21. 10E-pharmacy & medicine delivery
  22. 10E-diagnostics & lab aggregation
  23. 10Provider & clinical software
  24. 11Chronic-care & remote monitoring
  25. 11Health & wellness / preventive
  26. 11Health insurtech & claims
  27. 11Market structure and the path of consolidation
  28. 12The investors and the deal map
  29. 12Capital requirements and the fundraising reality
  30. 12The hard yards: why ventures fail, how winners solve it
  31. 13Urban versus rural, and the route to market
  32. 13Case study: the platform plays and the public platform
  33. 13The buyers: who pays for digital health
  34. 13Emerging opportunities and the technology landscape
  35. 14Reimbursement and the four unit-economics models
  36. 14Vertical in focus: mental health
  37. 14Vertical in focus: femtech and elder care
  38. 15The deal map: landmark M&A
  39. 15Notable rounds, standings and the IPO question
  40. 15The forces shaping the year
  41. 15The download was never the business
  42. 16Distribution moves to where acquisition is free
  43. 16Compliance is the new distribution
  44. 16The wedge is the payer
  45. 17Value moves down the acuity curve
  46. 17Frugal, sovereign AI relieves the binding constraint
  47. 18The buyer's ground
  48. 18The only date that binds
  49. 19Registration is not adoption
  50. 20The money, and why nobody can tell you how much
  51. 22Who is actually profitable
  52. 23PM-JAY: the scheme as a counterparty
  53. 24What a buyer pays, and what cannot be priced
  54. 26Teleconsultation at scale, and what the numbers do not say
  55. 27The Gulf comparison
  56. 29Three numbers to stop quoting
  57. 31The year ahead: the Calls
  58. 31How the Calls are made and graded
  59. 31The Calls: 2027, at a glance
  60. 31Calls one to three
  61. 32Calls four to six
  62. 32Calls seven and eight
  63. 32Calls nine and ten
  64. 33By domain, and three scenarios
  65. 33The market, the technology, the rules, the capital
  66. 33Bull, base and bear: 2027
  67. 34What to watch, and the record
  68. 34The operator's playbook: what to do with the year
  69. 34Regulatory annex: the segment crosswalk
  70. 35The data appendix: the sector in numbers
  71. 35Methodology, sources & glossary
  72. 35The risk register
  73. 36Talent, organisation and compliance
  74. 362027, in one view
  75. 36The watchlist
Volge Quarterly is Volge's signature series, published every quarter for enterprise customers.
Volge · Panache Editions · The Indian Digital Health edition
Indian Digital HealthVolge Quarterly01 •

The year the market starts paying for unit economics

2027 is the year India's digital-health market stops paying for growth and starts paying for unit economics.

The bind­ing con­straint in In­dian di­gital health was never reg­u­la­tion, and it was never cap­ital. It is the gap between what a cus­tomer costs to ac­quire and what a cus­tomer is worth. A tele­con­sulta­tion ac­quired for ₹800–2,000 against a single con­sulta­tion worth ₹300–800 is a sub­sidy dressed as a busi­ness, and the mar­ket spent the bet­ter part of a dec­ade fund­ing the sub­sidy. That era is over. In 2027 the sub­sidy ends, and the busi­nesses that sur­vive are the ones whose arith­metic already works.

Two kinds of com­pany clear the bar. The first is the multi-seg­ment plat­form (the Tata 1mg or the PharmEasy) that owns tele­con­sulta­tion, phar­macy and dia­gnostics to­gether, so a single ac­quired cus­tomer is mon­et­ised across sev­eral trans­ac­tions and the cost of ac­quis­i­tion is amort­ised rather than ab­sorbed. The second is the busi­ness that never paid for ac­quis­i­tion at all: the cor­por­ate group-health seller, the pro­vider-soft­ware vendor, the ven­ture that rides the ABDM pub­lic rails into dis­tri­bu­tion it did not have to buy. The single-ser­vice con­sumer app, bought one ex­pens­ive down­load at a time, is the loser of the year.

Acquisition cost was the whole story, and it was always going to end.

This is not a pess­im­istic read. The mar­ket is large (roughly $15–18 bil­lion in 2025) and the struc­tural de­mand is real: India has about 1.1 doc­tors per 1,000 people against 2.8 in the de­veloped world, and 70% of its spe­cial­ists serve the urban third of the pop­u­la­tion. The op­por­tun­ity to reach pop­u­la­tions that have never had re­li­able ac­cess to qual­ity care is genu­ine and vast. What changes in 2027 is the dis­cip­line with which cap­ital is al­loc­ated against that op­por­tun­ity. Fund­ing has re­boun­ded (about $1.13 bil­lion across 112 deals in 2024) but it now screens for unit eco­nom­ics, not growth, and it has re­priced the 2021 co­hort without sen­ti­ment.

The year's quieter story is where value mi­grates. It moves down the acu­ity curve and away from the crowded front door of acute tele­con­sulta­tion: to­wards chronic-care man­age­ment, pro­vider soft­ware and the pub­lic-rail in­fra­struc­ture, where re­ten­tion is higher and mar­gins hold. It moves to­wards the payer, as health in­sur­ance be­comes the largest seg­ment of India's

non-life mar­ket and group and out-pa­tient cover begin, at last, to re­lieve the out-of-pocket trap that cre­ated the unit-eco­nom­ics prob­lem in the first place. And it moves to­wards frugal, sov­er­eign ar­ti­fi­cial in­tel­li­gence: small, Indic-lan­guage, voice-first mod­els that cut the cost to serve and ex­tend the scarce clini­cian, at­tack­ing the one con­straint the sec­tor can­not en­gin­eer around.

The Calls in this edi­tion put num­bers and dates to those move­ments. They are writ­ten to be graded a year from now. Read them as the firm's con­sidered judge­ment on a sec­tor at an in­flec­tion, and as a stand­ing in­vit­a­tion to mark our home­work in 2028.

The Ed­it­ors, Volge Quarterly · 2027

The state of the sector

A ~$15–18 billion market chasing $100 billion by 2033, built on the collision of severe healthcare undersupply with mass digital adoption and the ABDM public rails, where unit economics, not regulation, decide survival.

The sector in numbers

The reconciled basis used throughout this edition, on one page. Where credible sources disagree on scope, a range is given rather than a false point estimate.

  • Mar­ket size, 2025: ~$15–18B, Broad di­gital-health scope; nar­rower tele­health defin­i­tions sit near $3.9B
  • 2033 pro­jec­tion: $100B+, ~20–25% CAGR; a dir­ec­tion, not a fore­cast
  • Health-tech star­tups: ~11,000, ~90% pre-rev­enue or sub-₹1 crore rev­enue
  • 2024 fund­ing: ~$1.13B, Across 112 deals; ~$496M in Q1 2025 across 38 rounds
  • ABHA ac­counts is­sued: 93 crore+, PIB, 6 July 2026
  • eSanjeevani con­sulta­tions: 50.01 crore, Cu­mu­lat­ive since 2019, to Septem­ber 2026 (MoHFW)

The arithmetic that governs

  • CAC to con­sult value: ~2–6×, ₹800–2,000 ac­quis­i­tion vs ₹300–800 per con­sult
  • Top-5 rev­enue con­cen­tra­tion: ~60%, In tele­con­sulta­tion and e-phar­macy
  • Health share of non-life in­sur­ance: ~41%, Largest non-life seg­ment, FY25

Re­con­ciled from Cus­tom Mar­ket In­sights, Mordor In­tel­li­gence, the Na­tional Health Au­thor­ity / ABDM dash­board, IRDAI and in­dustry fund­ing track­ers (2024–26). Ranges re­flect genu­ine source dis­agree­ment on scope. Cur­rent to June 2026. Drawn from Volge's in­ternal sec­tor play­book .

Indian Digital HealthVolge Quarterly02 •

The one-line read

A large, fast-grow­ing mar­ket on a broad and shal­low base (most of its 11,000 firms sub-scale) where the test that sep­ar­ates win­ners from the rest is cus­tomer-ac­quis­i­tion cost against life­time value, not mar­ket size.

Where the sector stands

Digital health is software meeting a healthcare system that is large, fragmented and undersupplied, and the present moment is distinct because three conditions have arrived together.

India's di­gital-health mar­ket is es­tim­ated at roughly $15–18 bil­lion in 2025 and is pro­jec­ted to ex­ceed $100 bil­lion by 2033, a com­pound rate in the order of 20–25%. The op­por­tun­ity rests on a struc­tural con­di­tion: severe un­der­sup­ply of phys­ical health­care meet­ing rapid di­gital ad­op­tion and a na­tional pub­lic di­gital-health stack. Un­like medtech, di­gital health is soft­ware (it it­er­ates quickly and scales on mod­est cap­ital) and its bind­ing con­straint is neither reg­u­la­tion nor cap­ital but unit eco­nom­ics.

That dis­tinc­tion or­gan­ises the whole sec­tor. A device com­pany is gated by clin­ical val­id­a­tion, reg­u­lat­ory class and man­u­fac­tur­ing cap­ital, and it earns over years. A di­gital-health com­pany faces none of these in the same de­gree; it can launch on mod­est cap­ital and it­er­ate weekly. What it can­not es­cape is the arith­metic of ac­quis­i­tion and re­ten­tion. Sur­vival turns on life­time value: re­peat use, cross-sell into phar­macy and dia­gnostics, or a shift to lower-cost busi­ness-to-busi­ness and gov­ern­ment chan­nels.

Cap­ital has re­boun­ded from the 2023 cor­rec­tion, but it is se­lect­ive, and it now re­wards pos­it­ive unit eco­nom­ics over growth. The win­ners cluster in plat­forms that own mul­tiple seg­ments and in the lower-cost chan­nels: cor­por­ate, gov­ern­ment and in­fra­struc­ture. The shape of the year fol­lows dir­ectly from that sen­tence.

Unlike medtech, the constraint is not approval or capital. It is the gap between what a customer costs and what a customer is worth.

The chapters that fol­low take the sec­tor apart in order: the three global mod­els and why India's is dis­tinct; the three forces be­hind the in­flec­tion; the seven-seg­ment tax­onomy and each seg­ment's eco­nom­ics; the pub­lic rails; the unit-eco­nom­ics test worked through in num­bers; the payer prob­lem and its es­cape route; the reg­u­lat­ory patch­work; the com­pet­it­ive and fund­ing

land­scape; the ar­rival of gen­er­at­ive AI; and the ver­tic­als be­neath the main­stream that are grow­ing fast­est.

India versus the world: three models

Three structural models of digital health have emerged worldwide. India's is distinct from both of the others, and the contrast explains both its opportunity and its central difficulty.

The United States runs a payer-led model: es­tab­lished re­im­burse­ment codes and a con­cen­trated in­surer sys­tem un­der­write tele­health and re­mote mon­it­or­ing, so the mon­et­isa­tion prob­lem is solved by the payer and the bind­ing con­straint is cost. China runs a super-app model, in which con­sumer-in­ter­net and in­sur­ance con­glom­er­ates built closed loops of con­sulta­tion, phar­macy, de­liv­ery and in­sur­ance. India runs a pub­lic-rails model: the gov­ern­ment built the iden­tity and in­ter­op­er­ab­il­ity layer (ABDM) and a na­tional telemedi­cine ser­vice (eSanjeevani), on which private plat­forms build.

MarketModelMonetisation engineExemplars
United StatesPayer-ledInsurer reimbursement codesTeladoc; Amazon Health
ChinaSuper-app / conglomerateClosed loop: consult + pharmacy + insurancePing An Good Doctor (400M+ users); JD Health; AliHealth
IndiaPublic-rails + private platformsOut-of-pocket; emerging insurance & governmentABDM / eSanjeevani; Tata 1mg; PharmEasy

Sources: GlobeNewswire (China telemedi­cine, 2025); com­pany dis­clos­ures. China telemedi­cine is pro­jec­ted at ~$18.9B by 2034. Cur­rent to June 2026.

The con­sequence is pre­cise. Dis­tri­bu­tion in India is cheaper be­cause the rails are shared, but mon­et­isa­tion is harder be­cause there is no dom­in­ant payer. India's de­fin­ing fea­ture is there­fore neither the US payer nor the Chinese super-app, but pub­lic in­fra­struc­ture that lowers the cost of reach while leav­ing the unit-eco­nom­ics prob­lem un­solved. Every stra­tegic choice in the sec­tor is, at root, an an­swer to that single asym­metry.

The first con­di­tion is struc­tural un­der­sup­ply: too few doc­tors, too few beds, and a spe­cial­ist work­force con­cen­trated in the cit­ies. The second is a di­gital in­flec­tion: more than 800 mil­lion in­ter­net users and over 500 mil­lion smart­phone users, with 4G reach­ing tier-2 and tier-3 cit­ies. The third is policy and cap­ital: the Ay­ush­man Bharat Di­gital Mis­sion, gov­ern­ment telemedi­cine through eSanjeevani, and re­newed in­vestor ap­pet­ite after the 2023 cor­rec­tion.

Sources: Min­istry of Health & Fam­ily Wel­fare; ABDM / Na­tional Health Au­thor­ity; in­dustry re­port­ing. In­dic­at­ors cur­rent to June 2026.

Indian Digital HealthVolge Quarterly03 •

Why India, why now

India's digital-health expansion is not incidental. It sits at the intersection of three conditions that have arrived at the same time.

ConditionIndicatorSignificance
Structural undersupply~1.1 doctors / 1,000 (vs 2.8); ~1.5M bed shortageDemand the physical system cannot meet
Specialist concentration~70% of specialists serve the urban ~30%The access gap digital health addresses
Digital inflection800M+ internet, 500M+ smartphone usersThe distribution channel for care
Out-of-pocket spend~60% of health expenditureShapes pricing and the payer problem
Public railsABDM; eSanjeevani; PM-JAYGovernment-built distribution and identity layer

The window

The con­di­tions de­scribe an open­ing, not a guar­an­tee. Mar­kets con­sol­id­ate quickly, unit eco­nom­ics de­cide which mod­els sur­vive, and reg­u­lat­ory clar­ity in sev­eral seg­ments (e-phar­macy most of all) re­mains un­settled. First movers with de­fens­ible mod­els and dur­able unit eco­nom­ics win dis­pro­por­tion­ately; un­dif­fer­en­ti­ated dir­ect-to-con­sumer entrants do not.

The seven segments

Digital health is wide and fast-moving. To read it coherently this edition commits to a single framework: seven segments on a horizontal layer of public rails, with clinical AI as a cross-cutting capability rather than a peer.

#SegmentDefinition
1Teleconsultation & telemedicineRemote clinical consultation by video, audio or text
2E-pharmacy & medicine deliveryOnline ordering and fulfilment of medicines
3E-diagnostics & lab aggregationBooking, home collection and reporting of tests
4Provider & clinical softwareSoftware sold to hospitals, clinics and doctors
5Chronic-care & remote monitoringContinuous management of long-term conditions
6Health & wellness / preventiveDirect-to-consumer preventive health and fitness
7Health insurtech & claimsTechnology for insurance distribution and claims

Ca­non­ical tax­onomy. Two lay­ers sit out­side the seven: the pub­lic rails (ABDM, eSanjeevani), which are in­fra­struc­ture; and clin­ical AI, a cross-cut­ting cap­ab­il­ity. Cur­rent to June 2026.

The frame­work is de­signed to be col­lect­ively ex­haust­ive: every di­gital-health busi­ness re­solves to one of

the seven, and most plat­forms com­bine sev­eral. Clin­ical ar­ti­fi­cial in­tel­li­gence is de­lib­er­ately not a seg­ment of its own: it ap­pears across the seven as triage in tele­con­sulta­tion, image and re­port read­ing in dia­gnostics, and a fea­ture of pro­vider soft­ware. Treat­ing it as a peer would double-count the over­lap, so it is read here as a ho­ri­zontal cap­ab­il­ity that raises the de­fens­ib­il­ity of whichever seg­ment it sits within.

India's position is inversely related to acquisition cost: strongest where revenue recurs, weakest where each customer must be bought again.

The segments in depth

Each segment carries a distinct economic and competitive profile, and a thesis should be explicit about which it is buying. The matrix consolidates share, economics, regulation, India's position and the leaders.

SegmentShare & economicsRegulatory statusIndia's positionLeading players
1 · Teleconsultation~45% of revenue; high CAC, low single-consult valueTelemedicine Guidelines 2020Crowded; survival needs repeat or B2BPracto, Apollo 24|7, MediBuddy, Tata 1mg
2 · E-pharmacyLargest by revenue; thin margins (15–25%)Unsettled: draft rules pending since 2018Consolidated; scale & logistics the moatPharmEasy, Tata 1mg, Netmeds, Apollo
3 · E-diagnostics~30% with e-pharmacy; capital-intensiveNABL / ISO 15189 accreditationGrowing; logistics & trust the moatTata 1mg, Redcliffe, Orange Health, Healthians
4 · Provider softwareRecurring SaaS; lower CAC, stickyABDM compliance; data governanceUnderbuilt; ABDM creates demandEka Care, HealthPlix, Practo Ray, Halemind
5 · Chronic-care & RPMBetter economics; recurringDPDP; device overlapPromising; higher LTV & retentionBeatO, Fitterfly, Phable, Wellthy
6 · Wellness / preventive~10%; D2C, high CAC, brand-ledLight-touch; consumer protectionCrowded; premium positioning neededHealthifyMe, Cult.fit, Ultrahuman
7 · Insurtech & claimsFast-growing; ~29% CAGRIRDAI regulatedMaturing; group health the wedgeOnsurity, Plum, Nova Benefits, Policybazaar

Shares re-cut from an earlier four-way es­tim­ate; pro­vider soft­ware, chronic-care and in­sur­tech are not sep­ar­ately quan­ti­fied. In­dic­at­ive; cur­rent to June 2026.

Indian Digital HealthVolge Quarterly04 •

The shape of the matrix

The pat­tern is con­sist­ent. India is strongest in the re­cur­ring, sticky, busi­ness-to-busi­ness-fla­voured seg­ments (pro­vider soft­ware, chronic-care, in­sur­tech) and hard­est in the crowded, high-ac­quis­i­tion-cost con­sumer seg­ments, tele­con­sulta­tion and well­ness. Tele­con­sulta­tion, the largest by rev­enue, is the most eco­nom­ic­ally dif­fi­cult: ac­quis­i­tion cost ex­ceeds the value of a single con­sulta­tion, and it com­petes against a free pub­lic al­tern­at­ive in eSanjeevani. E-phar­macy is the largest by ab­so­lute rev­enue and the most con­sol­id­ated, but runs on con­tested legal ground. Pro­vider soft­ware car­ries the best eco­nom­ics in the sec­tor (re­cur­ring rev­enue, lower ac­quis­i­tion cost, high switch­ing costs) and is the clearest in­fra­struc­ture play.

The segments in depth: the profiles

1 · Teleconsultation & telemedicine

The largest seg­ment by rev­enue share, at roughly 45%, and the most eco­nom­ic­ally dif­fi­cult. The unit-eco­nom­ics ceil­ing is most acute here, be­cause ac­quis­i­tion cost ex­ceeds the value of a single con­sulta­tion, and the seg­ment com­petes against the free pub­lic al­tern­at­ive of eSanjeevani. Sur­vival de­pends on mov­ing away from one-off acute con­sulta­tion to­wards re­peat use, spe­cialty depth and busi­ness-to-busi­ness chan­nels. The moat is clin­ical qual­ity, spe­cialty focus and brand, not price.

2 · E-pharmacy & medicine delivery

The largest seg­ment by ab­so­lute rev­enue and the most con­sol­id­ated, dom­in­ated by con­glom­er­ate-backed plat­forms. Mar­gins are thin, 15–25%, so prof­it­ab­il­ity de­pends on scale, private label, chronic-re­fill sub­scrip­tions and data. It car­ries the sec­tor's single largest policy risk, since the gov­ern­ing rules have never been no­ti­fied. The moat is scale and sup­ply-chain depth.

3 · E-diagnostics & lab aggregation

Book­ing, home col­lec­tion and di­gital re­port­ing of tests: about 30% of rev­enue with e-phar­macy. Home sample col­lec­tion is op­er­a­tion­ally com­plex and cap­ital-in­tens­ive, which is where the moat sits: lo­gist­ics, turn­around time, trust and ac­cred­it­a­tion. Con­tested by di­gital-nat­ive ag­greg­at­ors and by off­line patho­logy chains mov­ing on­line.

4 · Provider & clinical software

Elec­tronic re­cords, prac­tice man­age­ment and clinic plat­forms sold to pro­viders (the best eco­nom­ics in the sec­tor: re­cur­ring rev­enue, lower ac­quis­i­tion cost, high switch­ing costs). Un­der­built re­l­at­ive to the op­por­tun­ity, and ABDM is now cre­at­ing fresh de­mand for com­pli­ant, in­ter­op­er­able sys­tems. For many in­vestors, the most de­fens­ible play.

5 · Chronic-care & remote monitoring

Ma­ter­i­ally bet­ter unit eco­nom­ics than acute tele­con­sulta­tion, be­cause the re­la­tion­ship is re­cur­ring and re­ten­tion is higher. Dia­betes and car­diac pro­grammes lead, com­bin­ing coach­ing, mon­it­or­ing and con­nec­ted devices, which places the seg­ment at the over­lap with medtech. The moat is out­comes data and sus­tained en­gage­ment; re­im­burse­ment re­mains nas­cent.

6 · Health & wellness / preventive

Con­sumer well­ness (fit­ness, nu­tri­tion, pre­vent­ive health), a dir­ect-to-con­sumer, brand-led seg­ment of roughly 10% of rev­enue. Ac­quis­i­tion cost is high and churn is a con­stant risk, so the moat is brand, com­munity and, in some cases, hard­ware.

7 · Health insurtech & claims

The fast­est-grow­ing seg­ment, ex­pand­ing around 29% a year, and the most stra­tegic­ally im­port­ant, be­cause it is the wedge into the payer prob­lem that con­strains the rest of the sec­tor. Group health lowers ac­quis­i­tion cost and brings re­cur­ring, em­ployer-fun­ded rev­enue. Reg­u­lated by IRDAI; con­sol­id­a­tion has begun.

ABDM metricFigure (2026)
ABHA health-account IDs issued93 crore+
Health records linked104 crore+
Facilities registered5.47 lakh+
ABDM-certified private firms1,000+

Source: PIB, 6 July 2026 (ac­counts and re­cords) and 12 Au­gust 2026 (re­gis­tries).

Indian Digital HealthVolge Quarterly05 •

The public rails: ABDM and eSanjeevani

India's distinguishing asset in digital health is a government-built public infrastructure: a national health-identity and interoperability layer, and the world's largest government-led telemedicine service. One is free distribution; one is also a public competitor.

ABDM: the identity and interoperability layer

The Ay­ush­man Bharat Di­gital Mis­sion is­sues the ABHA iden­ti­fier (a unique health ID that lets re­cords move across pro­viders) and sets the stand­ards through which sys­tems ex­change data. As of July 2026 it had is­sued over 93 crore ABHA ac­counts and linked over 104 crore health re­cords (PIB, 6 July 2026), and by Au­gust 2026 over 5.47 lakh fa­cil­it­ies stood on the Health Fa­cil­ity Re­gistry and over 10.50 lakh pro­fes­sion­als on the Health­care Pro­fes­sion­als Re­gistry (PIB, 12 Au­gust 2026). More than 1,000 private firms are ABDM-cer­ti­fied, a net­work ef­fect that com­pounds with every par­ti­cipant.

eSanjeevani: the public telemedicine service

Launched in 2019, eSanjeevani is the world's largest gov­ern­ment-led telemedi­cine ini­ti­at­ive. By 15 Septem­ber 2026 it had de­livered 50.01 crore tele­con­sulta­tions across 36 states and union ter­rit­or­ies, with women ac­count­ing for 57.14 per cent of use (MoHFW, 6 Oc­to­ber 2026), sup­por­ted by roughly 220,000 pro­viders and in­teg­rated with ABDM; more than 127,000 Health and Well­ness Centres func­tion as telemedi­cine hubs. For a private plat­form it is both a demon­stra­tion of lat­ent de­mand and a free pub­lic al­tern­at­ive in basic con­sulta­tion, which is pre­cisely why private tele­con­sulta­tion must com­pete on spe­cialty, qual­ity and con­veni­ence rather than price.

The builder thesis

A ven­ture can au­then­tic­ate pa­tients through ABHA, find pro­viders through the re­gis­tries, ex­change re­cords through the con­sent man­ager, and, through the Uni­fied Health In­ter­face (UHI), let a pa­tient on any app dis­cover and book any par­ti­cip­at­ing pro­vider. UHI car­ries the po­ten­tial to un­bundle the closed plat­forms, turn­ing dis­cov­ery and book­ing into an open net­work rather than a walled garden. The net­work is still early, and build­ing on gov­ern­ment rails car­ries de­pend­ency on their pace.

Re­con­ciled from Cus­tom Mar­ket In­sights, Mordor In­tel­li­gence and in­dustry track­ers. Ranges re­flect genu­ine source dis­agree­ment on scope. Cur­rent to June 2026.

Market economics: the unit-economics test

The market is large and fast-growing, but its defining economic feature is not its size. It is that the businesses within it are gated by unit economics rather than by capital or clinical approval.

MeasureFigure (2025)Note
Digital-health market size~$15–18B$17.81B on a broad basis (Grand View Research, 2025); Custom Market Insights is materially lower at $8.79B (2024)
2033 projection$100B+~$107B at ~25% CAGR (CMI)
Growth (CAGR)~20–25%Varies by segment and scope
Telehealth sub-market~$3.9B (2025) → ~$9.8B (2030)~20% CAGR (Mordor)
Startup base~11,000~90% pre-revenue or sub-₹1 cr revenue
2025 funding~$0.70B / 54 dealsFell from the ~$1.13B 2024 rebound (Inc42, 2026)

The arithmetic, worked through

Con­sider a dir­ect-to-con­sumer tele­con­sulta­tion ven­ture with an ac­quis­i­tion cost of ₹1,200 and a first con­sulta­tion priced at ₹500 at a 50% gross mar­gin: a con­tri­bu­tion of ₹250. That first trans­ac­tion re­cov­ers only a fifth of the ac­quis­i­tion cost. To reach a healthy life­time value of three to five times ac­quis­i­tion cost, the ven­ture must gen­er­ate ₹3,600–6,000 of con­tri­bu­tion per user, roughly four­teen to twenty-four fur­ther con­sulta­tions, or far fewer if each visit is bundled with a dia­gnostic test or phar­macy order at higher mar­gin. The same user ac­quired through a cor­por­ate con­tract at ₹300, gen­er­at­ing re­cur­ring an­nual rev­enue, re­pays within months.

The platform and B2B models change the denominator of the ratio, not merely the numerator. That is the entire argument.
ModelCACGross marginEconomic logic
D2C teleconsultation₹800–2,000+40–60%A single consult never repays CAC; viable only via repeat, cross-sell or high-ticket
E-pharmacyModerate; volume-led15–25%Thin margins; profit through scale, private label, data; logistics-heavy
Platform (multi-segment)Amortised across streamsBlendedOne acquisition monetised across consult, pharmacy, diagnostics; 18–24 months to profit
B2B / corporate & SaaS₹150–500 per userRecurring, stickyLower CAC, higher LTV, longer sales cycle; the most defensible economics
Indian Digital HealthVolge Quarterly06 •

Il­lus­trat­ive mod­els, in­dic­at­ive only. Cur­rent to June 2026.

The payer problem, and the escape route

The unit-economics trap exists because India has no dominant payer for digital care, so the cost of acquisition falls on the venture rather than on an insurer. The escape route is the deepening of the payer base, and that base is now growing quickly.

Out-of-pocket spend­ing dom­in­ates, at over 60% of health ex­pendit­ure. AB PM-JAY is vast, at over 500 mil­lion be­ne­fi­ciar­ies, but un­der­fun­ded and slow to re­im­burse. Cor­por­ate group health is grow­ing but con­cen­trated in the tech­no­logy and fin­ance sec­tors. Most ven­tures there­fore de­pend on out-of-pocket or cor­por­ate rev­enue, which makes ac­quis­i­tion cost the de­cis­ive met­ric.

The shift now under way is in in­sur­ance. Health in­sur­ance be­came the largest seg­ment of India's non-life mar­ket in FY25, at about 41% of gross premium, over­tak­ing motor. The health-in­sur­ance mar­ket is es­tim­ated at roughly $16 bil­lion in 2025 and pro­jec­ted to reach about $48.5 bil­lion by 2035, a com­pound rate near 12%. The white spaces are pre­cisely the ones that would re­lieve the di­gital-health prob­lem: out-pa­tient cover, men­tal-health cover, senior in­clu­sion, rural pen­et­ra­tion and pre­ven­tion-led en­gage­ment.

Payer poolScale & directionRelevance to digital health
Out-of-pocket60%+ of health spend; the default todayThe source of the CAC trap
Private health insurance~$16B (2025) → ~$48.5B (2035), ~12% CAGROPD & group cover is the escape route
Corporate group healthGrowing; employer-fundedLowest-CAC channel; the insurtech wedge
Government (PM-JAY)500M+ beneficiaries; teleconsult reimbursement emergingVolume; slow and low reimbursement

Sources: IRDAI; Mordor In­tel­li­gence and IMARC (2025); IRDAI senior-premium cap (Janu­ary 2025). Cur­rent to June 2026.

Why insurtech is strategic

As out-pa­tient and group cover deepen, the sec­tor's de­pend­ence on out-of-pocket pay­ment eases and the route to sus­tain­able unit eco­nom­ics opens. This is why health in­sur­tech, the sev­enth seg­ment, is stra­tegic­ally the most im­port­ant: it is the wedge into the payer.

Sources: MoHFW; CDSCO; Delhi High Court dir­ec­tion (Nov 2023); DPDP Act 2023. Cur­rent to June 2026.

Regulation: a patchwork still settling

Digital health is governed by a patchwork of instruments rather than a single code. Some are clear; others (e-pharmacy above all) remain unsettled after years, and that ambiguity is itself a determinant of which models are financeable.

InstrumentScopeStatus
Telemedicine Practice Guidelines 2020Who may practise; consent; prescriptions; recordsIn force; cross-state licensure friction remains
E-pharmacy draft rulesOnline sale of medicinesDrafted Aug 2018; never notified; under court direction since 2023
Drugs & Cosmetics Act 1940 / Rules 1945Dispensing, prescription, storageIn force; e-pharmacies comply with offline rules in the interim
Digital Personal Data Protection Act 2023Health-data consent, localisation, deletionEnacted; penalties up to ₹250 crore
NABL / ISO 15189Diagnostic-lab accreditationIn force for labs
CDSCO: Software as a Medical DeviceClinical AI as a regulated deviceAI diagnostic software is Class C; final guidance CDSCO/MD/GD/MDSW/01/2026, 21 July 2026, carries an Algorithm Change Protocol
IRDAIInsurance distribution and claimsIn force for insurtech

The e-pharmacy vacuum

The most con­sequen­tial gap is e-phar­macy. Draft rules to amend the Drugs and Cos­met­ics Rules were is­sued in Au­gust 2018 but have never been no­ti­fied. In Novem­ber 2023 the Delhi High Court dir­ec­ted the cent­ral gov­ern­ment to frame a policy within eight weeks, ob­serving that the rules had been pending for over five years. In the in­terim, on­line phar­ma­cies op­er­ate under the ex­ist­ing off­line drug law. The ef­fect is a large, con­sol­id­ated seg­ment run­ning on con­tested legal ground: a stand­ing risk to any e-phar­macy thesis, and a reason valu­ations there carry a reg­u­lat­ory dis­count.

Con­sol­id­a­tion is the ex­pec­ted path: the win­ners ex­pand ho­ri­zont­ally into phar­macy, dia­gnostics and in­sur­ance, while un­der­cap­it­al­ised single-seg­ment play­ers are ac­quired or exit. An es­tim­ated 20–30% of the base is likely to fail or be ab­sorbed over the next two years. The sec­tor has moved through four phases: found­a­tion (2005–15), the telemedi­cine boom (2015–20), con­sol­id­a­tion and the 2023 cor­rec­tion (2020–23),

Indian Digital HealthVolge Quarterly07 •

and the present phase of prof­it­ab­il­ity and de­fens­ib­il­ity (2024 on­ward).

The competitive landscape

Capital and revenue are concentrating. The top five firms control roughly 60% of revenue in teleconsultation and e-pharmacy; beneath them is a long, fragmented tail of some 11,000 startups, most pre-revenue.

CompanyRevenue (latest)FocusStatus
PharmEasy (API Holdings)₹6,869 cr (FY26)E-pharmacy, diagnosticsPrivate; IPO deferred; 2024 down round
Tata 1mg₹2,936 cr (FY26)Integrated platformTata Digital-backed
HealthKart₹1,021 crNutrition & wellness (D2C)Profitable (₹38 cr PAT FY24)
Cult.fit₹927 crFitness & wellnessNarrowing losses
MediBuddy₹645 cr (→ ₹743 cr FY25)Corporate group healthLosses cut ~37%
Pristyn Care₹601 crSurgery-care platformValuation ~$1.17B (Nov 2025)
Healthians₹243 crE-diagnosticsEBITDA breakeven (FY24)
Practo₹240 crDiscovery, teleconsultUnicorn ($1.2–1.5B)

Per com­pany fil­ings and En­trackr / Inc42 re­port­ing (FY24, with FY25 where dis­closed). Ranked by FY24 op­er­at­ing rev­enue. Cur­rent to June 2026.

The leaders increasingly own several segments at once, so segment boundaries are becoming commercial rather than strict.

The funding anatomy

Funding has rebounded from the 2023 correction, but it is disciplined: it rewards positive unit economics, platform breadth and a credible path to profit, and it has repriced the consumer-health businesses that scaled on growth alone.

In­dian health-tech­no­logy star­tups raised ap­prox­im­ately $1.13 bil­lion across 112 deals in 2024, with about $496 mil­lion across 38 rounds in the first quarter of 2025 alone. Roughly 30% of health-tech­no­logy ven­ture cap­ital now flows to medtech and dia­gnostics rather than to pure tele­con­sulta­tion, and un­dif­fer­en­ti­ated dir­ect-to-con­sumer brands have seen early-stage fund­ing con­tract sharply. The re­pri­cing of the 2021 co­hort is the de­fin­ing fea­ture of the cycle: PharmEasy raised its 2024 round at a steep dis­count to its peak, and Pristyn Care's valu­ation stood at about

$1.17 bil­lion in Novem­ber 2025, down some 17% from its $1.4 bil­lion peak.

The defining force is strategic

Di­gital health draws a broad cap­ital base, but the most im­port­ant act­ors are stra­tegic: large do­mestic groups (Tata Di­gital, Re­li­ance Re­tail, Apollo) are the de­fin­ing ac­quirers and growth back­ers, and fam­ily of­fices such as Ran­jan Pai's Manipal vehicle have stepped in to re­price and sta­bil­ise the lar­ger plat­forms. The real­istic exit, for now, is stra­tegic ac­quis­i­tion or a private-equity sec­ond­ary rather than a pub­lic list­ing.

Landmark dealAcquirerTerms / significance
1mgTata Digital~65% stake (2021); Tata's entry into integrated digital health
NetmedsReliance Retail60% for ₹620 cr; Reliance's e-pharmacy entry
MedlifePharmEasyAll-stock (2021); created the largest online pharmacy
ThyrocarePharmEasy66.1% for ₹4,546 cr (2021); e-pharmacy buys a listed diagnostics chain
RenewBuyInsuranceDekho~₹7,400 cr merger (May 2025); the defining insurtech consolidation
PharmEasyRanjan Pai family office₹1,804 cr down round (2024); repricing of the e-pharmacy leader

Sources: Busi­ness Stand­ard, Inc42, En­trackr (2021–25); com­pany dis­clos­ures. Cur­rent to June 2026.

Generative AI across the sector

The defining development of 2025–26 is the arrival of generative AI as a horizontal capability across every segment. Adoption has been rapid: the share of Indian clinicians using AI tools rose from about 12% in 2024 to 41% in 2025, surpassing the United States and the United Kingdom.

Where it is landing

AI med­ical scribes: Eka Care's EkaScribe, built on its pur­pose-trained Par­rot­let mod­els, con­verts mul­ti­lin­gual doc­tor–pa­tient con­ver­sa­tions into struc­tured notes and pre­scrip­tions. Con­ver­sa­tional triage: Sar­vam AI de­ploys voice-en­abled, mul­ti­lin­gual agents that reach rural pa­tients through WhatsApp and low-band­width in­ter­faces. Health-reas­on­ing mod­els: Fractal's Vaidya 2.0 sup­ports emer­gency as­sist­ance and symp­tom check­ing. Pub­lic-health AI: gov­ern­ment de­ploy­ments in tuber­cu­losis and dia­betic-ret­ino­pathy screen­ing have been as­so­ci­ated with a 27% de­cline in ad­verse TB out­comes.

Indian Digital HealthVolge Quarterly08 •

India's dis­tinct­ive ad­vant­age is frugal, sov­er­eign AI: small, do­main-spe­cific mod­els that cut in­fer­ence costs by 60–97%, tuned for Indic lan­guages and voice-first, low-band­width use. The sig­ni­fic­ance is two­fold. Gen­er­at­ive AI lowers the cost to serve, and it at­tacks the bind­ing doc­tor-sup­ply con­straint by ex­tend­ing scarce clini­cians through triage, doc­u­ment­a­tion and de­cision sup­port.

Read correctly, generative AI is an accelerant across all seven segments, strongest where it relieves the labour constraint.

The caveats

Ac­cur­acy, gov­ernance, li­ab­il­ity and the DPDP Act all apply, and these sys­tems are po­si­tioned as de­cision sup­port rather than autonom­ous dia­gnosis. Sources: EY; PIB; Di­gital Health News; Rest of World; com­pany dis­clos­ures (2025–26).

The underserved verticals

Three verticals sit beneath the mainstream segments, underserved relative to need and growing quickly. Each cuts across the seven segments rather than replacing them, and each has begun to attract dedicated capital.

VerticalSignalRepresentative players
Mental healthStigma easing; corporate & insurer demandWysa (~$30M), Amaha (~₹100 cr, 2026), Lissun (~$5M)
Femtech / women's health~$310M (2025) → ~$3.87B (2030)Soothe, Plackal (Maya), Gytree, Janitri
Elder care / geriatric~$3B silver economy; ageing & PM-JAY 70+Emoha, KITES, Primus, Pranyaas

Sources: Inc42, Di­gital Health News, MyndStories; com­pany dis­clos­ures and Tracxn; Frost & Sul­li­van. Cur­rent to June 2026.

Men­tal-health tech­no­logy has moved from the mar­gins to a fund­able cat­egory. Wysa, a Bengaluru con­ver­sa­tional-sup­port plat­form, has raised about $30 mil­lion and re­ports more than five mil­lion users across 95 coun­tries; Amaha raised about ₹100 crore in Oc­to­ber 2026, in­clud­ing ₹10 crore of debt from Al­teria Cap­ital, at a post-money valu­ation near ₹350 crore. Women's-health tech­no­logy is the most de­veloped of the three, at roughly $310 mil­lion in 2025 and grow­ing to­wards $3.87 bil­lion by 2030, across a few hun­dred act­ive com­pan­ies. Elder care is earlier but struc­tur­ally sup­por­ted by an age­ing pop­u­la­tion and the AB PM-JAY ex­ten­sion to cit­izens aged 70 and above; Emoha closed a Series B1 of about ₹85 crore in July 2026 and

an­nounced the Shremoha senior-liv­ing joint ven­ture on 2 July 2026.

The global backdrop

The Indian opportunity is best read first against the global market, and then against the specific conditions that make India distinct.

Di­gital health is a large and fast-grow­ing global mar­ket, led by the United States, where es­tab­lished re­im­burse­ment codes and a con­cen­trated payer sys­tem un­der­write tele­health and re­mote mon­it­or­ing. The COVID-19 pan­demic nor­m­al­ised re­mote care world­wide, ad­van­cing ad­op­tion by years within months. India is a com­par­at­ively small but among the fast­est-grow­ing parts of this mar­ket; its dis­tin­guish­ing fea­tures are the scale of unmet de­mand and a gov­ern­ment-built pub­lic di­gital-health in­fra­struc­ture of a kind few other mar­kets pos­sess.

That pub­lic in­fra­struc­ture is the hinge. In the United States the payer solves mon­et­isa­tion and the con­straint is cost; in China the con­glom­er­ate super-app builds a closed con­sumer loop; in India the state builds the rails and the private sec­tor builds on top. The reach is cheaper and the mon­et­isa­tion is harder, and every later chapter is a vari­ation on that theme.

Why the contrast matters

An in­vestor pri­cing In­dian di­gital health against US or Chinese com­par­ables mis­reads it. The unit eco­nom­ics, the payer struc­ture and the dis­tri­bu­tion model are cat­egor­ic­ally dif­fer­ent, and the busi­nesses that travel are the ones built for India's pub­lic-rails real­ity, not im­por­ted from a payer-led mar­ket.

The builder thesis fol­lows. A ven­ture can au­then­tic­ate pa­tients through ABHA, find pro­viders through the re­gis­tries, ex­change re­cords through the con­sent man­ager, and, through UHI, let a pa­tient on any ap­plic­a­tion dis­cover and book any par­ti­cip­at­ing pro­vider. For founders, this lowers the cost of build­ing dis­tri­bu­tion and trust, and it is the clearest route to in­ter­op­er­ab­il­ity. UHI in par­tic­u­lar car­ries the po­ten­tial to un­bundle the closed plat­forms, since dis­cov­ery and book­ing be­come an open net­work rather than a walled garden.

The cau­tion is that the net­work is early. UHI ad­op­tion and its net­work ef­fects are nas­cent, and build­ing on gov­ern­ment rails car­ries de­pend­ency on their pace and un­even ma­tur­ity. The rails lower the cost of reach; they do not yet guar­an­tee the de­mand.

Source: Na­tional Health Au­thor­ity / ABDM; UHI doc­u­ment­a­tion. Cur­rent to June 2026.

Indian Digital HealthVolge Quarterly09 •

Building on the rails: the health stack

ABDM is best understood not as a registry of statistics but as a set of composable building blocks: an India Stack for health on which private applications build, rather than rebuilding identity, records and discovery for themselves.

BlockFunction
ABHA: health ID & addressA portable identity that ties a patient's records together across providers
HFR: Health Facility RegistryA national directory of hospitals, clinics, labs and pharmacies
HPR: Healthcare Professionals RegistryA verified directory of doctors and practitioners
HIE-CM: Consent ManagerConsent-driven exchange of records; the patient authorises each share
UHI: Unified Health InterfaceAn open network to discover, book, conduct and pay for services across any app: the UPI for health

Teleconsultation & telemedicine

Share & economics

~45% of rev­enue · high CAC, low single-con­sult value · the hard­est eco­nom­ics in the sec­tor.

Tele­con­sulta­tion is the largest seg­ment by rev­enue share and the most eco­nom­ic­ally dif­fi­cult. Its sub-seg­ments span gen­eral and spe­cialty con­sulta­tion, men­tal health, second opin­ions and tele-ICU. The unit-eco­nom­ics ceil­ing is most acute here, be­cause ac­quis­i­tion cost ex­ceeds the value of a single con­sulta­tion, and the seg­ment com­petes against a free pub­lic al­tern­at­ive in eSanjeevani.

Sur­vival there­fore de­pends on mov­ing away from one-off acute con­sulta­tion to­wards re­peat use, spe­cialty depth and busi­ness-to-busi­ness chan­nels. The moat is clin­ical qual­ity, spe­cialty focus and brand, not price. The firms that en­dure are those that con­vert a con­sulta­tion into a re­la­tion­ship (a chronic-care pro­gramme, a dia­gnostics order, a cor­por­ate con­tract) rather than a trans­ac­tion.

The leaders

Practo, Apollo 24|7, MediBuddy and Tata 1mg.

E-pharmacy & medicine delivery

Share & economics

Largest by ab­so­lute rev­enue · thin mar­gins (15–25%) · the sec­tor's single largest policy risk.

E-phar­macy is the largest seg­ment by ab­so­lute rev­enue and the most con­sol­id­ated, dom­in­ated by

con­glom­er­ate-backed plat­forms. Mar­gins are thin, so prof­it­ab­il­ity de­pends on scale, private label, chronic-re­fill sub­scrip­tions and data, and the busi­ness is lo­gist­ics-heavy.

It also car­ries the sec­tor's single largest policy risk, since the gov­ern­ing rules have never been no­ti­fied. A large, con­sol­id­ated seg­ment runs on con­tested legal ground, and that am­bi­gu­ity sits as a dis­count on every e-phar­macy valu­ation. The moat is scale and sup­ply-chain depth.

The leaders

PharmEasy, Tata 1mg, Net­meds (Re­li­ance) and Apollo Phar­macy.

E-diagnostics & lab aggregation

Share & economics

~30% with e-phar­macy · cap­ital-in­tens­ive home col­lec­tion · lo­gist­ics and trust the moat.

E-dia­gnostics (book­ing, home col­lec­tion and di­gital re­port­ing of tests) ac­counts, with e-phar­macy, for about 30% of rev­enue. Home sample col­lec­tion is op­er­a­tion­ally com­plex and cap­ital-in­tens­ive, which is where the moat sits: lo­gist­ics, turn­around time, trust and ac­cred­it­a­tion.

The seg­ment is con­tested by di­gital-nat­ive ag­greg­at­ors and by the es­tab­lished off­line patho­logy chains mov­ing on­line. Ac­cred­it­a­tion under NABL or ISO 15189 is the cred­ib­il­ity floor; lo­gist­ics and turn­around are the dif­fer­en­ti­ation above it.

The leaders

Tata 1mg Labs, Red­cliffe, Or­ange Health and Health­i­ans, against in­cum­bents such as Dr Lal and Met­ro­polis.

Provider & clinical software

Share & economics

Re­cur­ring SaaS · lower CAC, high switch­ing cost · the best eco­nom­ics in the sec­tor.

Pro­vider soft­ware (elec­tronic re­cords, prac­tice man­age­ment and clinic plat­forms sold to hos­pit­als, clin­ics and doc­tors) car­ries the best eco­nom­ics in the sec­tor: re­cur­ring rev­enue, lower ac­quis­i­tion cost and high switch­ing costs.

Indian Digital HealthVolge Quarterly10 •

It is also un­der­built re­l­at­ive to the op­por­tun­ity, and ABDM is now cre­at­ing fresh de­mand for com­pli­ant, in­ter­op­er­able sys­tems. The moat is switch­ing cost and the data that ac­crues. This is the clearest in­fra­struc­ture play and, for many in­vestors, the most de­fens­ible po­s­i­tion in In­dian di­gital health.

The leaders

Eka Care, HealthPlix, Hale­mind, Practo Ray and Bajaj Fin­serv Health.

Chronic-care & remote monitoring

Share & economics

Bet­ter eco­nom­ics than acute tele­con­sulta­tion · re­cur­ring, higher LTV · the medtech over­lap.

Chronic-care man­age­ment of­fers ma­ter­i­ally bet­ter unit eco­nom­ics than acute tele­con­sulta­tion, be­cause the re­la­tion­ship is re­cur­ring and re­ten­tion is higher. Dia­betes and car­diac pro­grammes lead, com­bin­ing coach­ing, mon­it­or­ing and, in­creas­ingly, con­nec­ted devices, which places the seg­ment at the over­lap with medtech.

The moat is out­comes data and sus­tained en­gage­ment; re­im­burse­ment re­mains nas­cent but is the up­side. As OPD and chronic-dis­ease cover deepen, this seg­ment is among the best po­si­tioned to con­vert en­gage­ment into a paid, re­cur­ring re­la­tion­ship.

The leaders

BeatO and Fit­ter­fly in dia­betes, with Phable and Well­thy across con­di­tions.

Health & wellness / preventive

Share & economics

~10% of rev­enue · D2C, high CAC, brand-led · the most de­bated as core health.

Con­sumer well­ness (fit­ness, nu­tri­tion and pre­vent­ive health) is a dir­ect-to-con­sumer, brand-led seg­ment, and the one whose clas­si­fic­a­tion as core health is most de­bated. Ac­quis­i­tion cost is high and churn is a con­stant risk, so the moat is brand, com­munity and, in some cases, hard­ware.

It is treated here as an ad­ja­cent con­sumer seg­ment rather than clin­ical care. The win­ners dif­fer­en­ti­ate on brand and, in­creas­ingly, on a hard­ware hook: the wear­able that turns a sub­scrip­tion into a habit.

The leaders

HealthifyMe, Cult.fit and Ul­trahu­man, the last dif­fer­en­ti­ated by its wear­able.

Health insurtech & claims

Share & economics

Fast­est-grow­ing (~29% CAGR) · IRDAI-reg­u­lated · the wedge into the payer.

Health in­sur­tech is the fast­est-grow­ing seg­ment and the most stra­tegic­ally im­port­ant, be­cause it is the wedge into the payer prob­lem that con­strains the rest of the sec­tor. Group health lowers ac­quis­i­tion cost and brings re­cur­ring, em­ployer-fun­ded rev­enue; claims tech­no­logy and be­ne­fits ad­min­is­tra­tion are the other entry points.

It is reg­u­lated by IRDAI and has begun to con­sol­id­ate, with the RenewBuy–InsuranceDekho mer­ger the de­fin­ing trans­ac­tion. The moat is dis­tri­bu­tion, em­ployer re­la­tion­ships and claims tech­no­logy: the as­sets that put an in­surer, not the pa­tient, on the other side of the trans­ac­tion.

The leaders

On­sur­ity, Plum, Nova Be­ne­fits, Even Health­care and Poli­cy­bazaar.

Market structure and the path of consolidation

The top five firms control roughly 60% of revenue in teleconsultation and e-pharmacy. Beneath them is a long, fragmented tail of some 11,000 startups, most pre-revenue.

Con­sol­id­a­tion is the ex­pec­ted path: the win­ners ex­pand ho­ri­zont­ally into phar­macy, dia­gnostics and in­sur­ance, while un­der­cap­it­al­ised single-seg­ment play­ers are ac­quired or exit. An es­tim­ated 20–30% of the base is likely to fail or be ab­sorbed over the next two years.

PhasePeriodDefining development
1 · Foundation2005–2015Practo founded (2008); doctor discovery; hospital and lab software
2 · Telemedicine boom2015–2020Telemedicine Guidelines (2020); COVID advances adoption by a decade in months
3 · Consolidation2020–2023Horizontal integration; SoftBank, Tiger, Accel flood capital; 2023 correction exposes unit economics
4 · Profitability & defensibility2024–presentCapital discipline returns; reimbursement begins to unlock; consolidation accelerates

Evol­u­tion of the sec­tor. Cur­rent to June 2026.

Indian Digital HealthVolge Quarterly11 •

The sec­tor now sits firmly in the fourth phase. The land grab is over; the de­fens­ib­il­ity con­test has begun, and it is won on unit eco­nom­ics, breadth and the data that ac­crues from own­ing the pa­tient re­la­tion­ship across seg­ments.

The investors and the deal map

Digital health draws a broader, more conventional capital base than medtech, because it carries software rather than hardware risk. The defining force, however, is strategic.

Investor typeRepresentative namesFocus
Healthcare-focused VCHealthQuad, W Health Ventures, 3one4, Kae CapitalHealth-specific early and growth
Generalist early-stage VCPeak XV, Accel, Lightspeed, Elevation, NexusSeries A–C across segments
Crossover / late-stageTiger Global, SoftBankLarge, later rounds in the 2021 cycle
Sovereign / global PETemasek, GIC, Prosus, General Atlantic, TPG GrowthScale platforms; e-pharmacy and diagnostics
Strategic / corporateTata Digital, Reliance Retail, ApolloAcquisition, distribution and stabilisation
Family officesRanjan Pai (Manipal / MEMG), Premji InvestRepricing and stabilising the larger platforms

Il­lus­trat­ive of where each tends to play. Cur­rent to June 2026.

Large do­mestic groups are the most im­port­ant ac­quirers and growth back­ers, and fam­ily of­fices have stepped in to re­price and sta­bil­ise the lar­ger plat­forms. The real­istic exit, for now, is a stra­tegic ac­quis­i­tion or a private-equity sec­ond­ary rather than a pub­lic list­ing, a fact that shapes how founders should build and how in­vestors should un­der­write.

Capital requirements and the fundraising reality

The capital map is conventional, but the bar at each stage has risen: every round now screens for unit economics, not just growth.

StageTypical sizeCriteriaTimeline
Seed / Pre-Seed₹1–5 crProblem validation; founding team; early traction6–12 months
Series A₹10–30 crProduct-market fit; unit-economics proof12–18 months
Series B₹50–150 crClear path to profitability; competitive moat18–24 months
Series C+₹200 cr+Profitability or a credible timeline; market leadership24+ months

In­dic­at­ive stage map. Cur­rent to June 2026.

What investors look for

Unit-eco­nom­ics in­sight: a cal­cu­lated CAC, LTV and pay­back, and a cred­ible path to profit. Trac­tion: act­ive users, re­ten­tion and re­peat rate show­ing genu­ine res­on­ance. Reg­u­lat­ory clar­ity: com­pli­ance, li­cens­ing and policy risk thought through, with no sur­prises. An un­fair ad­vant­age: pro­pri­et­ary data, clin­ical part­ner­ships, dis­tri­bu­tion or IP com­pet­it­ors can­not rep­lic­ate.

The hard yards: why ventures fail, how winners solve it

Most digital-health ventures fail not between prototype and approval, as in medtech, but between user acquisition and sustainable revenue.

Why some failed

The fail­ures are in­struct­ive. HealthcareMagic could not mon­et­ise; scarce high-qual­ity doc­tors and low-cost con­sulta­tions could not sup­port the eco­nom­ics. Med­well Ven­tures was cap­ital-in­tens­ive in labs and centres without sus­tain­able col­lec­tions. A broad co­hort of dir­ect-to-con­sumer health brands failed at a rate near 80%, com­pet­ing on price until mar­gins dis­ap­peared. In each case ac­quis­i­tion cost ex­ceeded life­time value at scale.

How winners solve it

The sur­viv­ors share four moves. The plat­form model (Tata 1mg, PharmEasy) owns tele­con­sulta­tion, phar­macy and dia­gnostics, so one ac­quired cus­tomer is mon­et­ised across sev­eral trans­ac­tions. The busi­ness-to-busi­ness chan­nel (MediBuddy) sells cor­por­ate group health at lower ac­quis­i­tion cost and higher re­ten­tion. Niche, high-ticket seg­ments such as chronic care, fer­til­ity and sur­gery carry higher fees and more re­peat vis­its. And the in­fra­struc­ture play sells to hos­pit­als and clin­ics rather than end users, with lower ac­quis­i­tion cost and re­cur­ring rev­enue.

The escape routes all do the same thing: they change who pays, how often, and at what cost to acquire.

In­dic­at­ive go-to-mar­ket eco­nom­ics. Cur­rent to June 2026.

Indian Digital HealthVolge Quarterly12 •

Urban versus rural, and the route to market

The market splits along a structural line, and the winning model is hybrid: high-margin urban operations subsidise rural expansion through public channels.

Urban tier-1 mar­kets ac­count for over 70% of plat­form rev­enue, with users will­ing to pay ₹500–1,500 a con­sulta­tion, but they are sat­ur­ated and com­mod­it­ised, and com­pet­i­tion is on price and con­veni­ence. The op­por­tun­ity there is spe­cial­isa­tion: men­tal health, fer­til­ity, der­ma­to­logy, and premium po­s­i­tion­ing. Rural and tier-2 and tier-3 mar­kets carry the lar­ger sup­ply gap, since 70% of spe­cial­ists serve the urban third, but they face in­fra­struc­ture bar­ri­ers and lim­ited will­ing­ness to pay, and the gov­ern­ment scheme is the primary chan­nel.

ChannelWhen it fitsEconomics
Direct-to-consumerDifferentiated or premium specialty careHigh CAC (₹1,000–2,500); viable only on high-ticket or add-on monetisation
Business-to-businessEmployee wellness; hospital and clinic softwareLower CAC (₹200–500), higher LTV; 3–6 month sales cycle
Government & public healthRural and underserved populationsMassive volume; slow (90+ day) and low (₹50–200) reimbursement
Platform / marketplaceAggregating services to cross-sellCAC amortised; 18–24 months to profit; capital-heavy

Case study: the platform plays and the public platform

The platform plays show how owning multiple segments rescues unit economics; eSanjeevani shows the size of the latent demand, and the public competitor private players must out-specialise.

Tata 1mg and PharmEasy

The two lead­ing plat­forms il­lus­trate the same solu­tion: own sev­eral seg­ments so that one ac­quired cus­tomer is mon­et­ised across many trans­ac­tions. Tata 1mg com­bines tele­con­sulta­tion, e-phar­macy and dia­gnostics under Tata Di­gital, reach­ing ₹2,936 crore of rev­enue in FY26, up 23 per cent on FY25 (En­trackr, 2026). PharmEasy, through API Hold­ings, built the largest on­line phar­macy (ex­ten­ded by the all-stock ac­quis­i­tion of Med­life) and re­por­ted con­sol­id­ated rev­enue near ₹6,869 crore in FY26, up about 14 per cent on FY25 (UnlistedZone, 2026), after a 2024 down round re­priced the busi­ness. Both show that scale and breadth, not a single high-mar­gin product, are the route to vi­ab­il­ity, and both show its cost: the cap­ital re­quired to build net­work ef­fects is large, and the path to profit runs to sev­eral years.

eSanjeevani: the public counter-example

As the Gov­ern­ment's na­tional telemedi­cine ser­vice, eSanjeevani has de­livered over 50 crore tele­con­sulta­tions since 2019, free at the point of use. Its scale proves that de­mand for re­mote con­sulta­tion is real and vast. For a private plat­form the im­plic­a­tion is pre­cise: the basic-con­sulta­tion seg­ment is oc­cu­pied by a free pub­lic al­tern­at­ive, so private tele­con­sulta­tion must com­pete on spe­cialty depth, clin­ical qual­ity, con­veni­ence and out­comes rather than price.

The buyers: who pays for digital health

Five buyer pools determine whose economics work. The whole sector is a contest to move revenue from the most expensive pool to the cheapest.

Buyer poolCharacterImplication
Consumers (out-of-pocket)Over 60% of health spend; dominant for D2CHigh CAC; price-sensitive; needs repeat or high-ticket
Corporates (group health)Employers buying employee wellnessLower CAC, higher LTV; concentrated in IT/finance
Hospitals & clinicsBuyers of provider SaaS and white-label teleconsultRecurring revenue; sticky; lower CAC
Insurers (private & insurtech)Coverage expanding; OPD and wellness add-onsReimbursement growing slowly; premium plans first
Government (PM-JAY, eSanjeevani)500M+ beneficiaries; massive volumeSlow, low reimbursement; demands capital efficiency

The five buyer pools. Cur­rent to June 2026.

The stra­tegic in­struc­tion is the same one the whole edi­tion re­turns to: a busi­ness that de­pends on the out-of-pocket con­sumer car­ries the highest ac­quis­i­tion cost in the sec­tor, while a busi­ness that earns the cor­por­ate, pro­vider or in­surer re­la­tion­ship car­ries the low­est. The mi­gra­tion from the first pool to the oth­ers is the work of 2027.

Emerging opportunities and the technology landscape

Four areas stand out as the next layer of opportunity, and each maps to a distinct technology and a distinct defensibility.

ABDM-nat­ive ser­vices built on the ABHA iden­tity and the gov­ern­ment health stack: a new layer with low du­plic­a­tion and in­her­ited dis­tri­bu­tion. AI-powered dia­gnostics: a heavy val­id­a­tion and reg­u­lat­ory bur­den, but in re­turn high de­fens­ib­il­ity and an ex­port angle. Chronic-care man­age­ment: ma­ter­i­ally bet­ter unit eco­nom­ics than acute tele­con­sulta­tion, through re­cur­ring en­gage­ment. Health­care lo­gist­ics: last-mile de­liv­ery

Indian Digital HealthVolge Quarterly13 •

and cold chain, cap­ital-in­tens­ive but high-mar­gin where solved.

The technology by segment

SegmentCore technologyKey consideration
TeleconsultationVideo, scheduling, paymentsABDM interoperability; data localisation
E-pharmacyOrder management, logistics, prescription verificationCold chain; drug-category compliance
DiagnosticsCollection scheduling, lab and report systemsAccuracy; NABL / ISO 15189 accreditation
Clinical AIML on imaging, ECG, pathologyClinical validation; CDSCO approval
Health records / SaaSEHR; ABDM-compliant exchangeInteroperability standards; governance

In­dic­at­ive tech­no­logy map by seg­ment. Cur­rent to June 2026.

Reimbursement and the four unit-economics models

India's payer landscape is fragmented, and that is the root of the unit-economics problem. Four models describe how ventures actually make the numbers work.

Un­like the United States, where Medi­care and Medi­caid are clear pay­ers, India has no dom­in­ant payer for di­gital care. Out-of-pocket spend­ing dom­in­ates at over 60% of health ex­pendit­ure; AB PM-JAY is vast at over 500 mil­lion be­ne­fi­ciar­ies but un­der­fun­ded and slow; cor­por­ate group health is grow­ing but con­cen­trated; private in­sur­ance cov­ers tele­con­sulta­tion only in premium plans. Most ven­tures there­fore de­pend on out-of-pocket or cor­por­ate rev­enue, which makes ac­quis­i­tion cost the de­cis­ive met­ric.

ModelCACMarginEconomic logic
D2C teleconsultation₹800–2,000+40–60%A single consult never repays CAC; viable only via repeat, cross-sell or high-ticket specialty
E-pharmacyModerate; volume-led15–25%Thin margins; profitability through scale, private label and data
Platform (multi-segment)AmortisedBlendedOne acquisition monetised across consult, pharmacy and diagnostics
B2B / corporate & SaaS₹150–500 per userRecurringLower CAC, higher LTV; the most defensible economics

Il­lus­trat­ive; in­dic­at­ive only. Cur­rent to June 2026.

The escape route

The route to sus­tain­able unit eco­nom­ics runs through the payer. As out-pa­tient and group cover deepen, the sec­tor's de­pend­ence on out-of-pocket pay­ment eases, which is why the in­sur­ance mar­ket, grow­ing

from ~$16B to­ward ~$48.5B by 2035, is the single most im­port­ant ex­ternal vari­able for di­gital health.

Vertical in focus: mental health

Mental-health technology has moved from the margins to a fundable category, as stigma eases and corporate and insurer demand grows.

The cat­egory now at­tracts ded­ic­ated cap­ital and re­ports genu­ine scale. Wysa, a Bengaluru-based con­ver­sa­tional-sup­port plat­form, has raised about $30 mil­lion from Google, pi Ven­tures and Kae Cap­ital, and re­ports more than five mil­lion users across 95 coun­tries. Amaha, formerly InnerHour, raised about ₹100 crore in Oc­to­ber 2026 at a post-money valu­ation near ₹350 crore, on FY25 rev­enue of ₹27.57 crore. Lis­sun raised about $2.5 mil­lion led by RPSG Cap­ital Ven­tures.

The eco­nom­ics are im­prov­ing be­cause the buyer is shift­ing. Cor­por­ate em­ployee-as­sist­ance con­tracts and in­surer well­ness add-ons move men­tal health off the high-ac­quis­i­tion-cost dir­ect-to-con­sumer model and onto the re­cur­ring, em­ployer-fun­ded chan­nel that the rest of the sec­tor is also chas­ing. Men­tal health is, in that sense, a lead­ing in­dic­ator of the payer mi­gra­tion the whole edi­tion de­scribes.

The categories that escape the consumer-acquisition trap first are the ones a corporate or an insurer agrees to fund.

Vertical in focus: femtech and elder care

Two further verticals sit beneath the mainstream, each structurally supported by demography and each beginning to attract dedicated capital.

Femtech / women's health

Women's-health tech­no­logy is the most de­veloped of the un­der­served ver­tic­als, at roughly $310 mil­lion in 2025 and grow­ing to­wards $3.87 bil­lion by 2030, with a few hun­dred act­ive com­pan­ies. The cat­egory spans fer­til­ity, ma­ter­nal health, men­strual health and gyn­ae­co­lo­gical care, and its de­fens­ib­il­ity rests on clin­ical cred­ib­il­ity and sus­tained en­gage­ment rather than on one-off trans­ac­tions. Rep­res­ent­at­ive play­ers in­clude Soothe, Plackal (Maya), Gytree and Jani­tri.

Indian Digital HealthVolge Quarterly14 •

Elder care / geriatric

Elder care is earlier but struc­tur­ally sup­por­ted by an age­ing pop­u­la­tion and the AB PM-JAY ex­ten­sion to cit­izens aged 70 and above; India's sil­ver eco­nomy is es­tim­ated near $3 bil­lion. Emoha closed a Series B1 of about ₹85 crore in July 2026; KITES fo­cuses on geri­at­ric, de­men­tia and pal­li­at­ive care; and Primus raised a ₹65-crore Series A led by the Manipal (Ran­jan Pai) fam­ily of­fice. The model com­bines care co­ordin­a­tion, re­mote mon­it­or­ing and at-home ser­vices: a chronic-care re­la­tion­ship by an­other name, with the same re­cur­ring-rev­enue ad­vant­age.

The deal map: landmark M&A

Deal activity has two faces: strategic consolidation, which provides the exits, and venture rounds, which provide the entry. In digital health the consolidation side is unusually developed: domestic conglomerates acquiring the segment leaders.

TargetAcquirerTerms / significance
1mgTata Digital~65% stake (2021); Tata's entry into integrated digital health
NetmedsReliance Retail60% for ₹620 cr (~$83M); Reliance's e-pharmacy entry
MedlifePharmEasy (API Holdings)All-stock (2021); created the largest online pharmacy
ThyrocarePharmEasy (API Holdings)66.1% for ₹4,546 cr (2021); e-pharmacy buys a listed diagnostics chain
AknamedAPI HoldingsAcquisition (2021); hospital and specialty supply-chain
Karkinos HealthcareRelianceStrategic investment (2024); distributed cancer care
RenewBuyInsuranceDekho~₹7,400 cr merger (May 2025); the defining insurtech consolidation
PharmEasyRanjan Pai family office₹1,804 cr down round (2024); repricing of the e-pharmacy leader

Sources: Busi­ness Stand­ard, Inc42, En­trackr (2021–25); com­pany dis­clos­ures. Cur­rent to June 2026.

The pat­tern is un­am­bigu­ous: the con­glom­er­ates (Tata, Re­li­ance and the Manipal group) are the de­fin­ing ac­quirers, and the seg­ment lead­ers are the tar­gets. For a founder, this shapes the en­dgame; for an in­vestor, it defines the real­istic exit.

Sources: Tracxn, Crunch­base, PitchBook and com­pany fil­ings (2024–26). Some fig­ures cu­mu­lat­ive. Cur­rent to June 2026.

Notable rounds, standings and the IPO question

The funding standings show where capital has concentrated, and the IPO question frames the only exit the sector has not yet proven.

CompanyFunding / standingFocus
PharmEasy (API Holdings)~$1.1B total; ₹1,804 cr down round (2024); FY26 revenue ₹6,869 crE-pharmacy & diagnostics
Tata 1mg~$240M raised; FY26 revenue ₹2,936 crIntegrated platform
Practo~$251M total; unicornDiscovery & teleconsultation
Pristyn Care~$187M total; valuation ~$1.17B (Nov 2025, down from $1.4B)Surgery-care platform
Eka Care~$19.5M totalABDM-native records & provider SaaS
OnsurityGrowth-fundedHealth insurtech (group)

The IPO question

The real­istic exit, for now, is stra­tegic ac­quis­i­tion or a private-equity sec­ond­ary rather than a pub­lic list­ing. PharmEasy's par­ent, API Hold­ings, filed for an ini­tial pub­lic of­fer­ing of up to ₹6,250 crore but with­drew it amid the 2022–23 cor­rec­tion; a re­vived list­ing is ex­pec­ted con­di­tional on the busi­ness turn­ing cash-flow pos­it­ive, with sev­eral ob­serv­ers point­ing to late 2026 at the earli­est. The pub­lic mar­ket gates entry on demon­strated prof­it­ab­il­ity (the same test that gov­erns the private rounds), so the like­li­est first list­ings are the plat­forms and in­sur­tech-ad­ja­cent busi­nesses that reach profit first.

There is no dominant payer for digital care in India. Every strategic choice in the sector is, at root, an answer to that single fact.

The state of the sec­tor · Volge Quarterly 2027

The forces shaping the year

Six through-lines cut across the segments. Each is a force that will move the sector in 2027, and together they explain the Calls that follow.

The download was never the business

Force 01 · Unit eco­nom­ics

A ₹800–2,000 ac­quis­i­tion against a ₹300–800 con­sulta­tion was a sub­sidy, not a model. For most of the last dec­ade, In­dian di­gital health fun­ded that sub­sidy with ven­ture cap­ital, and the head­line growth it

Indian Digital HealthVolge Quarterly15 •

bought was real but ren­ted. In 2027 the rent comes due: the cap­ital that once paid for ac­quis­i­tion now screens for the eco­nom­ics that make ac­quis­i­tion repay it­self.

Acquisition cost was the whole story, and it was always going to end.

The es­cape is arith­metic, not am­bi­tion. A busi­ness sur­vives only if life­time value clears ac­quis­i­tion cost by a wide mar­gin, and there are three hon­est ways to get there: re­peat use, cross-sell into higher-mar­gin phar­macy and dia­gnostics, or a move to chan­nels where ac­quis­i­tion is struc­tur­ally cheaper. The plat­forms that own mul­tiple seg­ments amort­ise the cost of a cus­tomer across years of trans­ac­tions; the single-ser­vice app can­not, and the mar­ket has stopped pre­tend­ing oth­er­wise.

The fail­ures are in­struct­ive. A broad co­hort of dir­ect-to-con­sumer health brands failed at a rate near 80%, com­pet­ing on price until mar­gins dis­ap­peared. In each case the cause was identical: ac­quis­i­tion cost ex­ceeded life­time value at scale, and no amount of growth closed the gap. 2027 is the year that les­son is fully priced in.

Distribution moves to where acquisition is free

Force 02 · Chan­nels

The win­ning chan­nels in 2027 by­pass paid ac­quis­i­tion en­tirely. Cor­por­ate group health ar­rives through the em­ployer; gov­ern­ment volume ar­rives through PM-JAY and eSanjeevani; and a ven­ture built on the ABDM pub­lic rails reaches pa­tients through in­fra­struc­ture it did not have to buy. The con­sumer app that must pur­chase each user one ad­vert­ise­ment at a time is struc­tur­ally short against a com­pet­itor whose users ar­rive for free.

The cheapest patient is the one you did not pay to acquire.

This is the prac­tical mean­ing of India's pub­lic-rails model. The gov­ern­ment built the iden­tity, the re­gis­tries and the con­sent layer; the firm that builds on them in­her­its dis­tri­bu­tion and trust at a frac­tion of the cost of man­u­fac­tur­ing its own. More than 127,000 Health and Well­ness Centres now func­tion as telemedi­cine hubs, ex­tend­ing the pub­lic chan­nel into rural India, and AB PM-JAY has begun to re­im­burse tele­con­sulta­tion in se­lect states.

The rev­enue mix is the tell. As pub­lic-rail and busi­ness-to-busi­ness chan­nels carry the ma­jor­ity of net new growth, the eco­nom­ics of the sec­tor quietly in­vert: the cheapest pa­tient is the one the busi­ness never paid to ac­quire, and the firms or­gan­ised around that fact out­last the ones or­gan­ised around the app store.

Compliance is the new distribution

Force 03 · Trust

The Di­gital Per­sonal Data Pro­tec­tion Act turns health data from an asset to be hoarded into a li­ab­il­ity to be gov­erned, and, for the firms that gov­ern it well, back into a moat. As the most sens­it­ive cat­egory under the Act, health data is where com­pli­ance stops being over­head and starts being a price of entry.

Compliance is the new distribution.

The ad­vant­age ac­crues un­evenly. A plat­form that can prove law­ful, per­mis­sioned, con­sent-man­aged data wins the en­ter­prise and gov­ern­ment con­tracts that a less dis­cip­lined com­pet­itor can­not touch, be­cause those buy­ers can­not af­ford the reg­u­lat­ory ex­pos­ure of a care­less vendor. Pen­al­ties of up to ₹250 crore con­cen­trate the mind, and the ABDM con­sent ar­chi­tec­ture gives the com­pli­ant a stand­ard to build to.

What looks like a bur­den in 2026 reads, by the end of 2027, as a com­pet­it­ive asset, and the gate through which the largest deals pass. The firms that treat data gov­ernance as a fea­ture, not a tax, find that it sells.

The wedge is the payer

Force 04 · The payer

Every unit-eco­nom­ics prob­lem in In­dian di­gital health traces back to one struc­tural fact: there is no dom­in­ant payer for di­gital care, so the cost of reach­ing a pa­tient falls on the ven­ture rather than on an in­surer. The most con­sequen­tial de­vel­op­ment of 2027 is that the payer base is fi­nally deep­en­ing.

As the payer deepens, the acquisition-cost trap loosens its grip on the whole sector.

Health in­sur­ance be­came the largest seg­ment of India's non-life mar­ket in FY25, at about 41% of gross premium, and is pro­jec­ted to roughly triple by 2035. The white spaces (out-pa­tient cover, men­tal-health cover, senior in­clu­sion, pre­ven­tion-led en­gage­ment)

Indian Digital HealthVolge Quarterly16 •

are pre­cisely the ones that would re­lieve the di­gital-health prob­lem. Group cover, em­ployer-fun­ded and re­cur­ring, is the low­est-ac­quis­i­tion-cost chan­nel in the sec­tor.

This is why health in­sur­tech, the sev­enth seg­ment, is stra­tegic­ally the most im­port­ant of the seven: it is the wedge into the payer, and the busi­nesses that own the em­ployer re­la­tion­ship and the claims rail are buy­ing the thing every other seg­ment lacks: someone other than the pa­tient to pay.

Value moves down the acuity curve

Force 05 · Value mi­gra­tion

The value in In­dian di­gital health is mi­grat­ing away from the crowded front door of acute tele­con­sulta­tion and to­wards the seg­ments where the re­la­tion­ship re­curs. Chronic-care man­age­ment (dia­betes, car­diac, ad­her­ence) car­ries ma­ter­i­ally bet­ter unit eco­nom­ics be­cause re­ten­tion is higher and the en­gage­ment is con­tinu­ous. Pro­vider soft­ware car­ries the best eco­nom­ics of all: re­cur­ring rev­enue, lower ac­quis­i­tion cost, high switch­ing costs.

The least glamorous segments of the consumer era are the ones whose economics now hold.

The dir­ec­tion of travel is con­sist­ent with where cap­ital now flows. Roughly 30% of health-tech­no­logy ven­ture cap­ital has ro­tated to­wards medtech, dia­gnostics and the re­cur­ring-rev­enue seg­ments, and away from pure tele­con­sulta­tion. The in­fra­struc­ture play (selling to hos­pit­als and clin­ics rather than to end users) is, for many in­vestors, the most de­fens­ible po­s­i­tion in the sec­tor.

The im­plic­a­tion for 2027 is that the league table re­orders. The busi­nesses that looked least glam­or­ous in the con­sumer-app era (the EHR vendor, the chronic-care pro­gramme, the claims plat­form) are the ones whose eco­nom­ics sur­vive con­tact with a dis­cip­lined mar­ket.

Frugal, sovereign AI relieves the binding constraint

Force 06 · Frugal AI

India's edge here is frugal­ity. Small, do­main-spe­cific, Indic-lan­guage mod­els cut in­fer­ence costs by 60–97% and run voice-first on low band­width, which matches the ac­tual con­di­tions of In­dian care de­liv­ery. Ad­op­tion has been fast: the share of clini­cians using AI tools rose from about 12% in 2024 to 41% in 2025, and the AI

scribe (EkaScribe and its peers) is on its way to be­com­ing table stakes for any plat­form at scale.

The one con­straint In­dian di­gital health can­not en­gin­eer around is the sup­ply of doc­tors: about 1.1 per 1,000 people, con­cen­trated in the cit­ies. Gen­er­at­ive AI is the first tech­no­logy that at­tacks that con­straint dir­ectly, by ex­tend­ing each scarce clini­cian through triage, doc­u­ment­a­tion and de­cision sup­port rather than by adding clini­cians the sys­tem does not have.

AI does not add doctors. It stretches the ones India already has, which is the only lever that scales.

The caveats are real: ac­cur­acy, li­ab­il­ity and the DPDP Act all bind, and these sys­tems are de­cision sup­port, not autonom­ous dia­gnosis. But read cor­rectly, frugal AI is the ac­cel­er­ant across all seven seg­ments, and it is strongest ex­actly where the sec­tor is weak­est: at the point where the cost to serve meets the short­age of people to serve.

Value moves down the acuity curve, distribution moves to where acquisition is free, and the payer finally begins to pay. Those three sentences are the year.

The forces · Volge Quarterly 2027

The Act was as­sen­ted on 11 Au­gust 2023 and then lay dormant, with no pro­vi­sion com­menced until Novem­ber 2025. The op­er­at­ive in­stru­ment is the Di­gital Per­sonal Data Pro­tec­tion Rules 2025, no­ti­fied as G.S.R. 846(E) by the Min­istry of Elec­tron­ics and In­form­a­tion Tech­no­logy with a gaz­ette date of 13 Novem­ber 2025; the 14 Novem­ber 2025 date that cir­cu­lates in com­ment­ary is the day the file was up­loaded, not the date of no­ti­fic­a­tion. A cor­ri­gendum, G.S.R. 892(E), fol­lowed on 10 Decem­ber 2025. Com­mence­ment is phased. The Board pro­vi­sions took ef­fect on 13 Novem­ber 2025, con­sent man­ager re­gis­tra­tion under Rule 4 and the First Sched­ule opens on 13 Novem­ber 2026, and the sub­stant­ive ob­lig­a­tions fol­low eight­een months after that.

What com­mences on 13 May 2027 is the whole com­pli­ance bur­den: no­tice, con­sent, se­cur­ity safe­guards, breach re­port­ing, re­ten­tion lim­its, data prin­cipal rights, chil­dren's data and Sig­ni­fic­ant Data Fi­du­ciary du­ties. Two pro­vi­sions are op­er­a­tion­ally heavy. Rule 6 re­quires en­cryp­tion or mask­ing, ac­cess con­trol, log­ging, backups and the re­ten­tion of logs for one year. Rule 7

Indian Digital HealthVolge Quarterly17 •

re­quires that a breach be in­tim­ated to each af­fected data prin­cipal and to the Board without delay, with a de­tailed re­port within sev­enty-two hours, and it sets no ma­ter­i­al­ity threshold: the loss of one re­cord is re­port­able on the same terms as the loss of one lakh.

The buyer's ground

What actually binds and when, where registration outruns adoption, who is in fact profitable, what a buyer pays, and three numbers in wide circulation that do not survive checking.

The only date that binds

One Indian digital health obligation carries a firm date and a consequence: 13 May 2027. Everything else in the field is recommendatory, held in abeyance, confined to adopting states, or undated.

The single bind­ing ob­lig­a­tion fa­cing an In­dian health­care pro­vider in this win­dow com­mences on 13 May 2027, when the sub­stant­ive du­ties under the Di­gital Per­sonal Data Pro­tec­tion Rules 2025 take ef­fect. They bind every hos­pital, dia­gnostics op­er­ator, phar­macy chain, in­surer and third-party ad­min­is­trator as a Data Fi­du­ciary, and there is no sec­toral carve-out for health­care. The in­stru­ments more often dis­cussed in board pa­pers carry no com­mence­ment date at all, be­cause they im­pose no ob­lig­a­tion from which a date could run. The dis­tinc­tion is com­mer­cial: a re­com­mend­at­ory stand­ard can be se­quenced at the buyer's con­veni­ence, and a gaz­ette-dated ob­lig­a­tion can­not.

Sig­ni­fic­ant Data Fi­du­ciary status is a des­ig­na­tion made by the Centre under sec­tion 10, and no en­tity has been no­ti­fied as one. The du­ties that would fol­low, under Rule 13, are an an­nual data pro­tec­tion im­pact as­sess­ment, an an­nual audit, an India-based data pro­tec­tion of­ficer and al­gorithmic due di­li­gence. On chil­dren's data, Rule 12 read with the Fourth Sched­ule names clin­ical es­tab­lish­ments and health­care pro­fes­sion­als among the ex­empt classes, but the scope of that ex­emp­tion is con­tested, and a blanket hos­pital ex­emp­tion should not be as­sumed.

The pen­alty fig­ures are taken from the Sched­ule to the Act as re­layed by sec­ond­ary sources and have not been read from the gaz­ette: up to Rs 250 crore for a se­cur­ity fail­ure, Rs 200 crore for a breach-no­ti­fic­a­tion fail­ure, Rs 200 crore on chil­dren's data, Rs 150 crore for Sig­ni­fic­ant Data Fi­du­ciary du­ties and Rs 50 crore re­sid­ual. No DPDP pen­alty has been im­posed on any en­tity.

Everything else, and why it does not bind

Tele­con­sulta­tion re­mains gov­erned by the Telemedi­cine Prac­tice Guidelines of 25 March 2020, is­sued by the Board of Gov­ernors in su­per­ses­sion of the Med­ical

Coun­cil of India as Ap­pendix 5 to the IMC (Pro­fes­sional Con­duct) Reg­u­la­tions 2002, and not res­cin­ded. The Na­tional Med­ical Com­mis­sion's Re­gistered Med­ical Prac­ti­tioner (Pro­fes­sional Con­duct) Reg­u­la­tions 2023, no­ti­fied on 2 Au­gust 2023, were held in abey­ance by an Eth­ics and Med­ical Re­gis­tra­tion Board no­tice of 23 Au­gust 2023; no evid­ence has been found that the abey­ance was lif­ted, and no suc­cessor was is­sued between 2024 and 2026. The re­gime in force is there­fore older than vendor lit­er­at­ure im­plies.

The only hard di­gital-re­cord ob­lig­a­tion on In­dian pro­viders sits in Rule 9(iv) of the Clin­ical Es­tab­lish­ments Cent­ral Rules 2012, which re­quires an es­tab­lish­ment to main­tain and provide an elec­tronic med­ical or health re­cord for every pa­tient. The par­ent Act of 2010 has been ad­op­ted in 19 states and union ter­rit­or­ies, and in all union ter­rit­or­ies ex­cept Delhi, as re­cor­ded on clin­icales­tab­lish­ments.mohfw.gov.in on a page last up­dated 30 Oc­to­ber 2026; Karnataka and Ker­ala op­er­ate sep­ar­ate re­gimes. The ob­lig­a­tion bites only in ad­opt­ing states, and the pen­alty under sec­tion 40 runs to Rs 10,000 for a first con­tra­ven­tion, Rs 50,000 for a second and Rs 5 lakh there­after. The EHR Stand­ards for India, re­vised in Decem­ber 2016, were is­sued as re­com­mend­a­tions states were ad­vised to adopt, and so are re­com­mend­at­ory in sub­stance.

Device and soft­ware li­cens­ing is the one area with settled dates be­hind it. The Med­ical Devices Rules 2017, G.S.R. 78(E) of 31 Janu­ary 2017, came into force on 1 Janu­ary 2018; li­cens­ing ap­plied from 1 Oc­to­ber 2022 for Class A and B devices and 1 Oc­to­ber 2023 for Class C and D, fol­low­ing the no­ti­fic­a­tion of 11 Feb­ru­ary 2020 that brought all devices within the drug defin­i­tion. The CDSCO Guid­ance Doc­u­ment on Med­ical Device Soft­ware, fi­nal­ised 21 July 2026 as Doc No. CDSCO/MD/GD/MDSW/01/2026, col­lapses the soft­ware-as-a-med­ical-device split into one cat­egory and per­mits an Al­gorithm Change Pro­tocol, but it is guid­ance and not bind­ing.

A recommendatory standard can be sequenced at the buyer's convenience. A gazette-dated obligation cannot.
InstrumentStatus todayDate
DPDP Rules 2025, substantive obligationsBinding on every Data Fiduciary, not yet commenced13 May 2027
DPDP Rules 2025, consent manager registrationBinding on consent managers only13 November 2026
Clinical Establishments Central Rules, Rule 9(iv)Binding, adopting states onlyIn force
Indian Digital HealthVolge Quarterly18 •
InstrumentStatus todayDate
Telemedicine Practice GuidelinesIn force, not rescinded25 March 2020
NMC Professional Conduct Regulations 2023Held in abeyance23 August 2023
EHR Standards for India, revised versionRecommendatory, states advised to adoptDecember 2016
CDSCO Medical Device Software guidanceGuidance, not binding21 July 2026
IRDAI health master circularOperative, no successor located29 May 2024
ABDM participationVoluntary, no statutory basisNo date published
NHCX onboardingNo mandate locatedNo date published

What fol­lows is a plan­ning win­dow, not a queue of dead­lines. Be­fore 13 May 2027 a pro­vider has to com­plete work that can­not be bought in a quarter: a re­cord of every pro­cessing flow and the law­ful basis for it; con­sent no­tices that work at re­gis­tra­tion, ad­mis­sion and dis­charge rather than on a web­site; en­cryp­tion, ac­cess con­trol and log­ging to Rule 6, with one year of log re­ten­tion; a breach drill tested against a sev­enty-two hour re­port and an in­tim­a­tion duty with no threshold; re­ten­tion sched­ules that sur­vive medico-legal prac­tice; and a de­cision on whether con­trac­ted pro­cessors, the hos­pital sys­tem vendor and the third-party ad­min­is­trator among them, are bound to the same terms. None of that work de­pends on the di­gital mis­sion, and none of it should wait on a man­date that has not been pub­lished.

Registration is not adoption

Of 5.33 lakh facilities registered on the Ayushman Bharat Digital Mission, 2.72 lakh are using mission-enabled software. The gap, and not the growth, is the operating fact for anyone planning around the mission.

The most use­ful pub­lished num­ber in In­dian di­gital health is a ratio, and it is close to one half. At the third ABDM Mis­sion Steer­ing Group meet­ing of 10 July 2026, chaired by the Union Health Min­is­ter, the mis­sion re­por­ted 5.33 lakh health fa­cil­it­ies on the Health Fa­cil­ity Re­gistry, of which 2.72 lakh were using ABDM-en­abled soft­ware: 51 per cent. The same meet­ing re­por­ted 93.95 crore ABHA num­bers, 105 crore linked health re­cords and 9.85 lakh pro­fes­sion­als on the Health­care Pro­fes­sion­als Re­gistry. That is the only of­fi­cial re­gistered-against-en­abled split avail­able, and it is the num­ber a buyer should carry. Re­gis­tra­tion is free, vol­un­tary and takes minutes; using en­abled soft­ware is a pro­cure­ment de­cision; and neither is the same as trans­act­ing, which is not pub­lished at all.

A method note that should be read be­fore any ABDM fig­ure is quoted. The mis­sion's live dash­board at dash­board.abdm.gov.in is a cli­ent-side JavaScript ap­plic­a­tion and can­not be read by a simple fetch, while abdm.gov.in serves a stale cached homepage still show­ing 14,15,49,620 Health IDs as on 03/12/2021. Every fig­ure in this chapter there­fore comes from a dated gov­ern­ment re­lease, a min­istry state­ment, or re­port­ing that cites the dash­board on a named date, and the proven­ance is given each time.

A tracker page dated 25 Septem­ber 2026 gives more than 5.6 lakh fa­cil­it­ies and about 11 lakh pro­fes­sion­als while leav­ing the soft­ware-en­abled count at 2.72 lakh. If that read­ing is ac­cur­ate, re­gis­tra­tions grew through the third quarter of 2026 while the en­abled count stood still, and the ratio fell below 51 per cent. It is a single sec­ond­ary source and not of­fi­cial, but it is con­sist­ent with the struc­ture of the pro­gramme: re­gis­tra­tion is pro­moted, soft­ware re­place­ment is not.

The 51 per cent fig­ure is in any event an upper bound. Health Fa­cil­ity Re­gistry fields, in­clud­ing whether a fa­cil­ity uses ABDM-com­pli­ant soft­ware, are self-de­clared and are not in­de­pend­ently veri­fied. One pub­lished veri­fic­a­tion rate stands against that: Karnataka is re­cor­ded at 93.9 per cent re­gistry veri­fic­a­tion, which also shows veri­fic­a­tion to be a state ef­fort rather than a na­tional one.

Where the funnel fails

The clearest ac­count of why the ratio stalls is a peer-re­viewed one. Kom­muru and Agar­wal, writ­ing in Health Man­age­ment Policy and In­nov­a­tion 11(2) on 9 July 2026 from the Stan­ford Gradu­ate School of Busi­ness, com­bined dash­board data with 15 in­ter­views con­duc­ted between Janu­ary and March 2026. Their find­ing is that mile­stone one, the cre­ation of ABHA iden­ti­fi­ers, has achieved mass scale, while mile­stone three, the one that would make the mis­sion genu­inely valu­able for care co­ordin­a­tion, re­mains ex­tremely low. They give no num­ber for it, be­cause the Na­tional Health Au­thor­ity pub­lishes no mile­stone three fig­ure. That ab­sence is it­self the most sig­ni­fic­ant gap in the pub­lic re­cord on In­dian health data ex­change.

The same paper loc­ates the steep­est drop-off between mile­stone two and mile­stone three, and at­trib­utes it to con­sent fric­tion rather than tech­no­logy. Pa­tients miss the no­ti­fic­a­tions on which re­trieval de­pends, and in pub­lic hos­pit­als where dia­gnostics are free, clini­cians were re­por­ted to find it more ex­pedi­ent to re­order a test than to nav­ig­ate the re­trieval work­flow. That is an eco­nomic find­ing rather than a tech­nical one, and any busi­ness case rest­ing on avoided du­plic­ate test­ing has to an­swer it.

Ra­jasthan il­lus­trates the gap in a single state. The state's in­teg­rated hos­pital man­age­ment sys­tem auto-en­rols an ABHA at the front desk, which pro­duces

Indian Digital HealthVolge Quarterly19 •

iden­ti­fier volume without ef­fort, yet the re­por­ted ABHA-to-elec­tronic-re­cord link­age rate is below 20 per cent. A second il­lus­tra­tion comes from the Centre's own new­est product: eSushrut@Clinic, built by C-DAC and launched in June 2026, had more than 2,200 fa­cil­it­ies on­boarded and had gen­er­ated just over 1,633 health re­cords, ac­cord­ing to the gov­ern­ment back­grounder of 6 July 2026. That is under one re­cord per on­boarded fa­cil­ity, and it is a cleaner ad­op­tion data­point than any dash­board total.

The de­nom­in­ator de­serves the same scep­ti­cism as the nu­mer­ator. The Stan­ford paper re­cords that CoWIN seeded roughly 130 mil­lion ac­counts without ex­pli­cit sep­ar­ate con­sent, and that a re-ap­plic­a­tion an­om­aly pro­duces du­plic­ates, with the con­sequence that the true de­nom­in­ator of unique act­ive pa­tients is sig­ni­fic­antly lower than head­line counts imply. The count of in­teg­rated private solu­tions is also un­settled: more than 450 in July 2026 re­port­ing, against more than 1,000 in the same journal in May 2026, with neither fig­ure trace­able to a named au­thor­ity doc­u­ment.

Measure, 10 July 2026 unless statedFigure
Facilities on the Health Facility Registry5.33 lakh
Of which using ABDM-enabled software2.72 lakh, 51 per cent
ABHA numbers issued93.95 crore
Linked health records105 crore
Professionals on the Healthcare Professionals Registry9.85 lakh
Scan and Register tokensAbout 24 crore
eSushrut@Clinic records, 2,200+ facilities, 18 June 20261,633
Published milestone three volumeNone

Linked re­cords are also con­cen­trated: in July 2026 Uttar Pra­desh ac­coun­ted for 15.03 crore, Andhra Pra­desh 11.95 crore, Bihar 7.37 crore, Ra­jasthan 6.32 crore and Gu­jarat 4.77 crore. A na­tional total above a bil­lion there­fore de­scribes a hand­ful of large pub­lic sys­tems rather than a uni­form cap­ab­il­ity.

Later dash­board read­ings re­layed by sec­ond­ary sources give 96.43 crore ABHA and more than 110 crore re­cords on 12 Au­gust 2026, 97.61 crore and 119.95 crore on 17 Septem­ber 2026, and 98.71 crore and 126 crore on 27 Oc­to­ber 2026. None is a primary cita­tion. It should also be noted that there is a CAG per­form­ance audit of AB-PMJAY but none of ABDM, and that the Par­lia­ment­ary Stand­ing Com­mit­tee's 144th Re­port of March 2023 cri­ti­cised PM-ABHIM, not ABDM, for spend­ing about 20 per cent of budget es­tim­ates.

Creating an identifier is free. Attaching a record to it is a procurement decision, and the published ratio shows which one has happened.

The takeaway is a change in the di­li­gence ques­tion. Whether a fa­cil­ity is re­gistered tells a buyer al­most noth­ing, be­cause re­gis­tra­tion is cost­less and self-de­clared. The ques­tions that carry in­form­a­tion are whether its soft­ware is cer­ti­fied at mile­stones two and three, what pro­por­tion of dis­charges pro­duce a linked re­cord, and what pro­por­tion of con­sent re­quests are answered. None is pub­lished na­tion­ally, and the reason mat­ters: the Na­tional Health Au­thor­ity is, in the words of the Stan­ford paper, a con­ven­ing and im­ple­ment­a­tion body and not a reg­u­lator. That paper's re­com­mend­a­tion fol­lows, namely re­pla­cing pay­ment per ABHA cre­ated with pay­ment for mile­stone two and three volume. Until some­thing of that kind hap­pens, 2.72 lakh is the ceil­ing on what can be re­lied upon.

The money, and why nobody can tell you how much

There is no primary source for Indian health-tech funding. Every figure in circulation originates with a commercial tracker, and the trackers disagree with each other and with themselves, in one case on two pages of the same website.

No reg­u­lator, ex­change or min­istry in India pub­lishes a health-tech fund­ing series. Every num­ber quoted in a board paper, a press re­lease or a mar­ket re­port be­gins life in a com­mer­cial tracker as­sembled from self-re­por­ted and press-re­por­ted rounds, each tracker using its own defin­i­tion of the sec­tor and each re­vis­ing its own his­tory without no­tice. The prac­tical con­sequence is that the level of In­dian health-tech in­vest­ment is not a known quant­ity in any year since 2021, and any fig­ure presen­ted as though it were should be read as one vendor's es­tim­ate. The shape of the series can be re­lied upon. The level can­not. This chapter sets out the dis­agree­ments year by year, be­cause a reader who has seen them will not again ac­cept a single fund­ing fig­ure as a fact.

Take 2021, the peak year and the one most often cited. Tracxn put it at USD 3.2 bil­lion in a March 2023 re­port, and at about USD 3.05 bil­lion on its live page in Novem­ber 2026. Inc42 put the same year at USD 2.19 bil­lion. The spread on a single, closed, five-year-old year is roughly one bil­lion dol­lars, which is a third of the lar­ger fig­ure. Noth­ing has changed in 2021 since 2021; what has changed is the defin­i­tion of what counts and the com­plete­ness of the col­lec­tion.

For 2022, Tracxn re­por­ted USD 1.4 bil­lion and a fall of 55 per cent, while Ven­ture In­tel­li­gence re­por­ted USD 1.07 bil­lion. For 2023, three fig­ures exist for one year, two of them from the same vendor: USD 438.2 mil­lion

Indian Digital HealthVolge Quarterly20 •

in the Tracxn an­nual re­port, USD 537 mil­lion on the Tracxn live page, and USD 682 mil­lion from Ven­ture In­tel­li­gence. The highest is 56 per cent above the low­est. For 2024, the Tracxn an­nual re­port gives USD 1.0 bil­lion, the Tracxn live page gives USD 1.23 bil­lion and Inc42 gives over USD 700 mil­lion, a di­ver­gence of about 75 per cent between the ex­tremes.

For 2025 the live Tracxn page gives USD 863 mil­lion while Inc42 gives about USD 700 mil­lion across 54 deals, a gap of some 23 per cent. The reas­ons for these gaps are not mys­ter­i­ous, and they are not er­rors in the or­din­ary sense. A tracker has to de­cide whether a dia­gnostics chain, a phar­macy de­liv­ery busi­ness, a hos­pital group rais­ing private equity, a med­ical device maker and an in­sur­ance dis­trib­utor be­long in health-tech, and the track­ers de­cide dif­fer­ently. It has to de­cide whether to count debt, ven­ture debt, sec­ond­ary trans­ac­tions and un­dis­closed rounds, and whether to carry an es­tim­ate where a round is un­an­nounced. Each de­cision is de­fens­ible on its own; the ag­greg­ate is not com­par­able.

The clearest single il­lus­tra­tion is the cur­rent year. For 2026 to date, one Tracxn page re­ports USD 626 mil­lion across 114 rounds to Septem­ber 2026 and de­scribes the trend as up 22.4 per cent. An­other Tracxn page re­ports USD 742 mil­lion across 52 rounds to Au­gust 2026 and de­scribes the trend as down 10.4 per cent. Same vendor, two pages, op­pos­ite dir­ec­tions, dif­fer­ent round counts, over­lap­ping peri­ods. It is to be noted that both fig­ures are in cur­rent cir­cu­la­tion and that neither car­ries a re­con­cili­ation.

YearFigures in circulationSpread
2021USD 3.2bn (Tracxn, March 2023); about USD 3.05bn (Tracxn live, November 2026); USD 2.19bn (Inc42)About USD 1bn
2022USD 1.4bn, down 55 per cent (Tracxn); USD 1.07bn (Venture Intelligence)About 31 per cent
2023USD 438.2mn (Tracxn annual); USD 537mn (Tracxn live); USD 682mn (Venture Intelligence)About 56 per cent
2024USD 1.0bn (Tracxn annual); USD 1.23bn (Tracxn live); over USD 700mn (Inc42)About 75 per cent
2025USD 863mn (Tracxn live); about USD 700mn across 54 deals (Inc42)About 23 per cent
2026 to dateUSD 626mn, 114 rounds to September, called +22.4 per cent; USD 742mn, 52 rounds to August, called -10.4 per centOpposite signs

Every fig­ure in the table above is tracker-de­rived. Tracxn, Ven­ture In­tel­li­gence and Inc42 are com­mer­cial data vendors; none of the fig­ures is filed with, audited by or pub­lished by any In­dian au­thor­ity, and the spreads shown are arith­metic com­par­is­ons of pub­lished claims rather than any vendor's own state­ment of error.

What can­not be con­cluded is any­thing that re­quires a level. The size of the mar­ket in any year can­not be stated. Year-on-year growth rates can­not be

cal­cu­lated, be­cause the nu­mer­ator and de­nom­in­ator may come from dif­fer­ent col­lec­tions or from the same col­lec­tion at dif­fer­ent vin­tages. Health-tech's share of total In­dian ven­ture fund­ing can­not be com­puted. Com­par­is­ons with other coun­tries' health-tech fund­ing, which rest on dif­fer­ent track­ers again, can­not be made. And no fig­ure in the series is cash in a com­pany: these are an­nounced rounds, not drawn-down cap­ital, and an­nounce­ment is where the tracker's in­form­a­tion ends.

What can and cannot be concluded

What can be con­cluded is the shape, be­cause every tracker agrees on it: a peak in 2021, a col­lapse in 2022, a trough in 2023, a par­tial re­cov­ery in 2024, and flat to down through 2025 and 2026. Three in­de­pend­ent col­lec­tions, how­ever dif­fer­ently they define the sec­tor, pro­duce the same con­tour. That con­tour is enough to sup­port a qual­it­at­ive judge­ment, namely that In­dian health-tech is five years past its fund­ing peak and has not re­turned to it, and that the re­cov­ery of 2024 did not con­tinue.

Three trackers agree on the shape of Indian health-tech funding and not one of them agrees on its size.

For a buyer the point is nar­rower and more use­ful than mar­ket siz­ing. Fund­ing totals are routinely offered as evid­ence of a vendor's dur­ab­il­ity, both by the vendor and by its com­pet­it­ors, and they can­not carry that weight: the num­ber is an es­tim­ate of an­nounced cap­ital at the sec­tor level, it says noth­ing about the in­di­vidual coun­ter­party's cash po­s­i­tion, and it may be re­vised after the con­tract is signed. The test that does carry weight is the filed one. An­nual ac­counts, audited rev­enue, re­por­ted losses and the dir­ec­tion of both are pub­lished for every com­pany of con­sequence in this sec­tor, and the fol­low­ing chapter uses them. Where the choice is between a tracker's es­tim­ate of what went into a sec­tor and a com­pany's own fil­ing of what came out, the fil­ing wins.

The hos­pital groups set the baseline. Apollo Hos­pit­als re­por­ted FY2026 rev­enue of Rs 25,229 crore, EBITDA of Rs 3,769 crore and profit after tax of Rs 1,942 crore, up 34 per cent. Fortis re­por­ted rev­enue of Rs 9,127.84 crore, EBITDA of Rs 2,085 crore at a 22.8 per cent mar­gin and profit after tax of Rs 1,064.19 crore. Max Health­care re­por­ted gross rev­enue of Rs 10,538 crore, EBITDA of Rs 2,638 crore at 26.2 per cent and profit

Indian Digital HealthVolge Quarterly21 •

after tax of Rs 1,631 crore. Naray­ana Hruday­alaya re­por­ted rev­enue of Rs 7,896.0 crore, up 44 per cent on the ac­quis­i­tion of Prac­tice Plus Group Hos­pit­als in the United King­dom, with re­por­ted profit after tax of Rs 810.5 crore and an ad­jus­ted fig­ure of Rs 937.4 crore.

Who is actually profitable

On filed FY2026 results the profitable parts of Indian healthcare are hospitals, diagnostics, pharmacy retail and insurance. Not one pure-play digital health platform has published a profit-after-tax-positive full year.

The profit in In­dian health­care sits with the asset own­ers and the risk car­ri­ers, and not with the plat­forms. For the year to 31 March 2026 every large lis­ted hos­pital group, every lis­ted dia­gnostics chain of scale, the largest lis­ted phar­macy re­tailer and the lis­ted health in­surers re­por­ted a profit after tax. No pure-play In­dian di­gital health plat­form has pub­lished a profit-after-tax-pos­it­ive full year, and the nearest ap­proach is an ad­jus­ted earn­ings meas­ure sit­ting above a net loss of Rs 520 crore. The party with the weaker bal­ance sheet is usu­ally the one seek­ing a multi-year com­mit­ment and hold­ing the pa­tient data.

Apollo HealthCo is the only dis­closed di­gital-arm seg­ment among the lis­ted hos­pital groups, and there­fore the only place where the eco­nom­ics of an In­dian di­gital health busi­ness can be read in­side a prof­it­able par­ent. It re­por­ted fourth-quarter FY2026 rev­enue of Rs 2,848 crore with EBITDA of Rs 156 crore against Rs 36 crore a year earlier, while seg­ment profit after tax for FY2025 was neg­at­ive Rs 27 crore. The cost of Apollo 24|7 was dis­closed at Rs 425.5 crore for the twelve months to Decem­ber 2024, and a de­mer­ger list­ing is tar­geted for the fourth quarter of FY2027. The strongest di­gital fran­chise in In­dian health­care, car­ried in­side the strongest hos­pital group, has thus reached seg­ment EBITDA pos­it­iv­ity and is not yet demon­strably prof­it­able in its own right.

Dia­gnostics and phar­macy re­tail are prof­it­able on thin­ner ab­so­lute num­bers. Dr Lal PathLabs re­por­ted FY2026 rev­enue of Rs 2,762.9 crore and profit after tax of Rs 509.8 crore, Thyro­care Rs 829.04 crore and Rs 162.85 crore, up 81 per cent, and Kr­snaa Dia­gnostics Rs 772.8 crore and Rs 101.3 crore. MedPlus re­por­ted rev­enue of Rs 6,892.5 crore and profit after tax of Rs 219.6 crore across 5,330 stores, a roughly 3 per cent net mar­gin on a phys­ical net­work. Met­ro­polis FY2026 could not be re­li­ably sourced; its FY2025 rev­enue was Rs 1,346 crore with profit after tax of Rs 145 crore.

The risk car­ri­ers and dis­trib­ut­ors are prof­it­able too. PB Fintech re­por­ted rev­enue of Rs 6,794 crore and profit after tax of Rs 670 crore, up 115 per cent, on premium of Rs 29,934 crore. Star Health re­por­ted gross writ­ten premium of Rs 20,369 crore, Ind AS profit after tax of Rs 911 crore and a com­bined ratio of 98.8 per cent; the nor­m­al­ised profit after tax of Rs 1,222 crore in its in­vestor deck is com­pany-defined. Niva Bupa re­por­ted IFRS profit after tax of Rs 366.10 crore on premium of Rs 9,432.9 crore. Medi As­sist, the third-party ad­min­is­trator, re­por­ted rev­enue of Rs 904.8 crore with re­por­ted profit after tax of Rs 89.3 crore, down on the year, and an ad­jus­ted fig­ure of Rs 68.8 crore. It is the only com­pany here whose ad­jus­ted profit is lower than its re­por­ted profit, every other ad­just­ment in the sec­tor mov­ing in the com­pany's fa­vour.

The pure plays

PharmEasy, fil­ing as API Hold­ings, re­por­ted FY2026 rev­enue of Rs 6,618.5 crore and a net loss of Rs 520 crore in its an­nual re­port, an im­prove­ment of 67 per cent on the pre­vi­ous year's Rs 1,572 crore loss, with group EBITDA of pos­it­ive Rs 62.5 crore. Tata 1mg re­por­ted FY2025 rev­enue of Rs 2,392 crore and a loss of Rs 276 crore, dis­closed through the Tata Sons an­nual re­port. Fig­ures for Practo, Pristyn Care and HealthifyMe are not pub­lish­able. Stated strictly: not one pure-play In­dian di­gital health plat­form has pub­lished a profit-after-tax-pos­it­ive full year, and the closest case is ad­jus­ted-EBITDA pos­it­ive while los­ing Rs 520 crore after tax.

CompanyFY2026 revenueFY2026 profit after tax
Apollo HospitalsRs 25,229 crRs 1,942 cr
Max HealthcareRs 10,538 cr grossRs 1,631 cr
FortisRs 9,127.84 crRs 1,064.19 cr
Narayana HrudayalayaRs 7,896.0 crRs 810.5 cr reported
MedPlusRs 6,892.5 crRs 219.6 cr
Dr Lal PathLabsRs 2,762.9 crRs 509.8 cr
ThyrocareRs 829.04 crRs 162.85 cr
PB FintechRs 6,794 crRs 670 cr
Star HealthRs 20,369 cr premiumRs 911 cr Ind AS
API Holdings, PharmEasyRs 6,618.5 crLoss of Rs 520 cr
Tata 1mg, FY2025Rs 2,392 crLoss of Rs 276 cr

The FY2026 fig­ures above are taken from res­ults re­leases as re­layed by trade press and should be re­con­ciled against the com­pan­ies' own ex­change fil­ings be­fore being quoted in a trans­ac­tion doc­u­ment. Re­port­ing bases dif­fer: Star Health is given on Ind AS, Niva Bupa on IFRS, and nor­m­al­ised or ad­jus­ted fig­ures are com­pany-defined in each case.

Valu­ation re­sets com­plete the pic­ture. PharmEasy was val­ued at USD 5.6 bil­lion at its 2021 peak; the April

Indian Digital HealthVolge Quarterly22 •

2024 rights issue of Rs 1,804 crore, led by Ran­jan Pai's MEMG, was struck at roughly a 90 per cent hair­cut im­ply­ing about USD 500 to 600 mil­lion. A Gold­man Sachs cov­en­ant de­fault was re­por­ted in June 2023 and the IPO pa­pers were re­called. Cap­ital has mean­while moved to as­sets: Naray­ana ac­quired Prac­tice Plus Group Hos­pit­als for GBP 183 mil­lion, an­nounced 31 Oc­to­ber 2025, and Apollo bought the In­ter­na­tional Fin­ance Cor­por­a­tion's 30.58 per cent of Apollo Health and Life­style for Rs 1,250 crore in Septem­ber 2025.

The profitable counterparties own beds, labs, shops or risk. The loss-making ones own the patient's data.

The takeaway is a di­li­gence in­struc­tion, not an in­vest­ment view. Where a plat­form is to hold clin­ical re­cords, op­er­ate a con­sent flow or stand between a pro­vider and a payer, its filed ac­counts be­long in the eval­u­ation along­side its func­tion­al­ity, as does the con­trac­tual an­swer to what hap­pens to the data if it fails. The sec­tor's exits argue for the ques­tion: JiviAI is lis­ted as hav­ing closed in June 2026 after rais­ing about USD 2.99 mil­lion, mfine is re­por­ted to have shut after USD 97 mil­lion, and DPIIT data cited in re­port­ing puts health­care and life-sci­ences clos­ures at 553 as at 31 Janu­ary 2026. None of the three is primary-sourced, and each is offered only as a reason to ask.

PM-JAY: the scheme as a counterparty

PM-JAY is a growing payer whose package rates have not been revised since 2022 and whose payment timeliness is now before two High Courts. For a provider the scheme is a credit decision before it is a volume decision.

The com­mer­cially sig­ni­fic­ant facts about PM-JAY are not its scale but its price and its pay­ment be­ha­viour. Base pack­age rates have not been re­vised since 2022, which is four years of flat tar­iffs against med­ical in­fla­tion. Pay­ment delays have moved from com­plaint to lit­ig­a­tion, with the Pun­jab and Hary­ana High Court is­su­ing no­tices in 2026 over per­sist­ent and sys­temic delays and the Hi­machal Pra­desh High Court or­der­ing re­lease within three weeks. And no of­fi­cial fig­ure for un­paid dues ex­ists in the pub­lic re­cord, so a pro­vider can­not size its ex­pos­ure from pub­lished data. A hos­pital de­cid­ing whether to deepen its em­pan­elled share is there­fore mak­ing a re­ceiv­ables judge­ment on in­com­plete in­form­a­tion, and should price it ac­cord­ingly.

The budget sets the ceil­ing. The 2026-27 budget es­tim­ate for PM-JAY is Rs 9,500 crore, up 5.56 per cent on the re­vised es­tim­ate for 2025-26, ac­cord­ing to the gov­ern­ment re­lease of 1 Feb­ru­ary 2026. The same re­lease puts the Health Min­istry total at Rs 1,06,530.42 crore, the Na­tional Health Mis­sion at Rs 39,390 crore and PM-ABHIM at Rs 4,770 crore. The di­gital health mis­sion ap­pears at Rs 350 crore in budget es­tim­ate against Rs 324.26 crore re­vised: a Rs 350 crore line in­side a Rs 1.07 lakh crore min­istry. Any­one as­sum­ing the mis­sion com­mands sig­ni­fic­ant cent­ral money should read that line twice.

Al­loc­a­tion has also his­tor­ic­ally ex­ceeded spend­ing. Between 2019 and 2022 the re­vised es­tim­ate ran at roughly half the budget es­tim­ate in each year, on ana­lysis by PRS and the Ac­count­ab­il­ity Ini­ti­at­ive. The exact series must be re­built from the Ex­pendit­ure Budget volumes, but the pat­tern is con­sist­ent enough to mat­ter: a rising budget es­tim­ate is a state­ment of in­tent, not a cash fore­cast.

Scale, by con­trast, is real and doc­u­mented. As at 28 Feb­ru­ary 2026 the scheme re­cor­ded 36,229 em­pan­elled hos­pit­als, 19,483 of them pub­lic and 16,746 private, and 11.69 crore ad­mis­sions au­thor­ised, of which 6.74 crore were in private hos­pit­als, on fig­ures re­lay­ing a gov­ern­ment re­lease of 23 March 2026. Private hos­pit­als there­fore carry about 58 per cent of au­thor­ised ad­mis­sions while hold­ing 46 per cent of em­pan­el­ment, the clearest pub­lished in­dic­a­tion of how far the scheme de­pends on private ca­pa­city. Ay­ush­man Vay Vandana, launched on 29 Oc­to­ber 2024 to cover those aged 70 and over for Rs 5 lakh, had is­sued 1.14 crore cards by 28 Feb­ru­ary 2026 against a quoted tar­get of about 6 crore seni­ors.

The price has not moved since 2022

Health Be­ne­fit Pack­age 2.2 took ef­fect in Novem­ber 2021. The 2022 re­vi­sion raised 832 rates, cut 122, left 630 un­changed and in­tro­duced dif­fer­en­tial pri­cing by city tier. No re­vi­sion after 2022 has been loc­ated, and none is sched­uled in any pub­lished doc­u­ment. For a pro­vider that means the re­im­burse­ment for a pro­ced­ure per­formed in 2026 is set at a 2022 price, with con­sum­ables, salar­ies, device costs and en­ergy all hav­ing moved in the in­terim. Where an em­pan­elled hos­pital's PM-JAY share rises, its blen­ded real­isa­tion falls, and the ef­fect com­pounds in the tiers where dif­fer­en­tial pri­cing already set the lower rate.

The pay­ment re­cord is doc­u­mented by the Comp­troller and Aud­itor Gen­eral. The per­form­ance audit tabled in Au­gust 2023 found in­or­din­ate delays in

Indian Digital HealthVolge Quarterly23 •

set­tle­ment, 39.57 lakh claims pro­cessed bey­ond the 12-hour pre-au­thor­isa­tion win­dow, ex­cess pay­ment of Rs 57.53 crore in four states, and 88,760 pa­tients re­cor­ded as hav­ing died dur­ing treat­ment against whom 2,14,923 sub­sequent claims were non­ethe­less re­gistered. The scheme's own rule is set­tle­ment within 15 days, ex­tend­able to 30. The audit es­tab­lishes that the rule was not being met at the time of audit; noth­ing pub­lished since es­tab­lishes that it is being met now.

The courts have since taken it up. The Pun­jab and Hary­ana High Court is­sued no­tices in 2026 over per­sist­ent and sys­temic delays. The Hi­machal Pra­desh High Court ordered re­lease of dues within three weeks and, sig­ni­fic­antly for any pro­vider ne­go­ti­at­ing with a state health agency, barred both a pending vi­gil­ance in­quiry and want of funds as grounds for with­hold­ing pay­ment. The sharpest data­point is com­mer­cial rather than ju­di­cial: about 650 private hos­pit­als in Hary­ana sus­pen­ded new ad­mis­sions for 24 hours on 1 and 2 Septem­ber 2026 over roughly Rs 1,200 crore pending bey­ond six months, as re­por­ted by Tribune India. A 24-hour with­drawal of ad­mis­sions by 650 hos­pit­als is a meas­ure of lever­age, used be­cause or­din­ary rem­ed­ies had not worked.

The CAG find­ings are drawn from the per­form­ance audit tabled in Au­gust 2023; the re­port num­ber could not be con­firmed and is there­fore not cited. The Hary­ana pending fig­ure of roughly Rs 1,200 crore is a single press source for one state and is not a na­tional total. No of­fi­cial fig­ure for un­paid PM-JAY dues, at any level, has been pub­lished. The Ay­ush­man Vay Vandana card count and the senior-pop­u­la­tion tar­get are from re­port­ing; no of­fi­cial doc­u­ment was ob­tained.

PM-JAY as a counterpartyPublished position
Budget estimate 2026-27Rs 9,500 crore, up 5.56 per cent on revised estimate
Empanelled hospitals, 28 February 202636,229: 19,483 public, 16,746 private
Admissions authorised, 28 February 202611.69 crore, of which 6.74 crore private
Last package rate revision2022
Settlement rule15 days, extendable to 30
Claims beyond the pre-authorisation window, CAG39.57 lakh
Official unpaid dues figureNone published
A tariff fixed in 2022 and a settlement rule that two High Courts have had to enforce are the two facts that decide whether empanelment is worth deepening.

The takeaway is that PM-JAY should be un­der­writ­ten and not merely joined. The ques­tions that fol­low from the pub­lished re­cord are the age pro­file of the

pro­vider's own out­stand­ing claims, the state agency's set­tle­ment his­tory as against the 15-day rule, whether the cur­rent case mix re­mains vi­able at 2022 rates and what pro­por­tion of ca­pa­city can be ex­posed to a single payer whose budget es­tim­ate has his­tor­ic­ally been halved at re­vi­sion. None of those ques­tions can be answered from a na­tional data­set, be­cause the na­tional data­set does not exist. They can be answered from a pro­vider's own ledger, and that is where the work has to be done.

The private payer, for com­par­ison, works to pub­lished turn­around times: under the IRDAI mas­ter cir­cu­lar of 29 May 2024, cash­less pre-au­thor­isa­tion within one hour, dis­charge au­thor­isa­tion within three hours and non-cash­less set­tle­ment within 15 days. No pen­alty is pub­lished for breach­ing the one-hour or three-hour stand­ard, and the Rs 1 crore per breach fig­ure quoted by vendors is the gen­eral sec­tion 102 power.

What a buyer pays, and what cannot be priced

Enterprise hospital software pricing in India is not published anywhere. The clearest public money in the field runs in the opposite direction: incentives paid to facilities for linking records.

A buyer can­not bench­mark the price of an In­dian hos­pital in­form­a­tion sys­tem from pub­lic sources, be­cause no In­dian en­ter­prise vendor pub­lishes a rate card. Insta by Practo, KareXpert, Medix­cel, DocEngage, At­tune, Napier, Suvarna, Birlamedis­oft and Plus91 are all quote-only. Bahmni, the open-source al­tern­at­ive, has a li­cence cost of zero and no pub­lished In­dian im­ple­ment­a­tion cost. What does exist in pub­lic is the money mov­ing the other way: the Di­gital Health In­cent­ive Scheme, which pays fa­cil­it­ies and soft­ware com­pan­ies for link­ing re­cords and whose dis­burse­ment is pub­lished. Price dis­cov­ery on the buy­ing side has to be done by tender, and this chapter sets out what can hon­estly an­chor one.

The fig­ures that cir­cu­late as In­dian soft­ware pri­cing are mar­ket­ing ranges from com­par­ison blogs, sev­eral of them writ­ten by com­pet­ing vendors, and they should be la­belled as such. One such page gives Rs 1,499 to Rs 15,000 per fa­cil­ity per month, or Rs 200 to Rs 500 per user per month (ad­rine.in, 2026). An­other gives Rs 2,000 to Rs 8,000 a month for clin­ics and Rs 8,000 to Rs 25,000 for hos­pit­als (cu­front.com, 2026). These are small-busi­ness cloud ranges, not trans­ac­tion prices. No en­ter­prise con­tract value for an In­dian hos­pital in­form­a­tion sys­tem has been found in the pub­lic do­main.

Indian Digital HealthVolge Quarterly24 •

One in­teg­ra­tion-cost es­tim­ate ex­ists, and de­serves quot­ing pre­cisely be­cause it is the only one. Kom­muru and Agar­wal, in Health Man­age­ment Policy and In­nov­a­tion 11(2) of 9 July 2026, from the Stan­ford Gradu­ate School of Busi­ness, state that in­teg­ra­tion costs for mid-sized pro­viders are es­tim­ated at Rs 30 to 50 lakh, de­rived from 15 in­ter­views con­duc­ted between Janu­ary and March 2026. It is in­ter­view-de­rived rather than a tender price, and cov­ers in­teg­ra­tion and not the un­der­ly­ing sys­tem.

The clearest public money

The Di­gital Health In­cent­ive Scheme is where gov­ern­ment money in In­dian di­gital health can ac­tu­ally be read. A gov­ern­ment back­grounder of 6 July 2026 re­ports dis­burse­ment as at 18 June 2026 of Rs 107 crore and above to hos­pit­als, Rs 2.95 crore to dia­gnostics, labs and phar­ma­cies, and Rs 26 crore and above to di­gital solu­tion com­pan­ies. The dis­tri­bu­tion is it­self a find­ing: hos­pit­als have claimed the over­whelm­ing share, dia­gnostics and phar­macy have barely en­gaged, and soft­ware vendors col­lec­ted roughly a quarter of the hos­pital total, con­sist­ent with a design that pays the vendor a share of the fa­cil­ity's in­cent­ive.

The rate struc­ture is widely re­por­ted and was not read from the au­thor­ity's own doc­u­ment. On the ori­ginal 2022 terms, a fa­cil­ity earned Rs 20 per ABHA-linked re­cord above a floor of 100 link­ing trans­ac­tions a month; a di­gital solu­tion com­pany took 25 per cent of the fa­cil­ity's in­cent­ive; an NHCX claim trans­ac­tion earned Rs 500 or 10 per cent of claim value, whichever was lower; and a cap of up to Rs 4 crore ap­plied per en­tity. Cor­ri­gendum 6, dated 20 Novem­ber 2025 under ref­er­ence S-12021/070/2022-ABDM(Coord)-Part(2), ex­ists, but the doc­u­ment would not render, so only its ex­ist­ence and date can be cited.

What happened to the rates af­ter­wards is not prop­erly pub­lic, and the dir­ec­tion mat­ters to any­one who has writ­ten in­cent­ive in­come into a busi­ness case. A Cor­ri­gendum 7, said to cover April to Septem­ber 2026 and to cut pay­ment to Rs 10 per KYC-veri­fied linked dis­charge sum­mary, Rs 5 for other re­cord types and Rs 200 per PM-JAY claim, is de­scribed only by third-party guides, though a Ra­jasthan Dir­ect­or­ate let­ter of 5 May 2026 cor­rob­or­ates the shift to pay­ing only for KYC-linked re­cords and adds per-day and per-month caps. The ex­piry date is not clearly pub­lic either: the last con­firmed ex­ten­sion runs to 31 Decem­ber 2023, yet pay­ments were flow­ing in June 2026.

Mile­stone one, two and three cer­ti­fic­a­tion through the au­thor­ity's sand­box is free; the vendor's own cost of achiev­ing it is not pub­lic. The Cor­ri­gendum 7

rates above are third-party de­scrip­tions of a doc­u­ment that could not be ob­tained and should not be re­lied upon in a budget.

Published price or paymentFigureStatus
Digital Health Incentive Scheme, hospitalsRs 107 crore and above disbursedGovernment backgrounder, as at 18 June 2026
Same scheme, diagnostics, labs, pharmaciesRs 2.95 crore disbursedGovernment backgrounder, as at 18 June 2026
Same scheme, digital solution companiesRs 26 crore and above disbursedGovernment backgrounder, as at 18 June 2026
Original incentive rateRs 20 per ABHA-linked record, cap up to Rs 4 croreWidely reported, not read from the authority's document
Integration cost, mid-sized providerRs 30 to 50 lakhInterview-derived estimate, July 2026
Hospital information system, small businessRs 1,499 to 15,000 per facility per monthMarketing range on a comparison blog
Enterprise hospital system contract valueNot publishedNo Indian vendor publishes a rate card
Assam medical college hospital systemAbout Rs 56.71 crore, seven hospitalsAward to RailTel, reported 2 January 2026

Pub­lic ten­der­ing gives two an­chors and no more. The only con­firmed 2026 award is to RailTel Cor­por­a­tion, at about Rs 56.71 crore, for a hos­pital man­age­ment in­form­a­tion sys­tem cov­er­ing seven med­ical col­lege hos­pit­als, awar­ded by Assam's Med­ical Edu­ca­tion and Re­search De­part­ment and re­por­ted on 2 Janu­ary 2026. Ker­ala's eHealth pro­gramme car­ried an ori­ginal cost of about Rs 96 crore, 90 per cent cent­rally fun­ded, with a later Rs 100 crore sanc­tion to ex­tend it to 349 more hos­pit­als; the Rs 3,000 crore World Bank-as­sisted pro­gramme in the state gov­ern­ment order of 1 July 2023 is a dif­fer­ent thing. Noth­ing veri­fi­able was found else­where.

Ser­vice prices are thin­ner still. Pub­lished con­sulta­tion list prices exist, from Rs 199 up­wards on the large private plat­forms and free to the cit­izen on the gov­ern­ment chan­nel, but con­tract and per-con­sulta­tion rates between busi­nesses are not pub­lic. On dia­gnostics the op­er­at­ive gov­ern­ment sched­ule is the CGHS re­vi­sion no­ti­fied on 13 Oc­to­ber 2025, with out­pa­tient con­sulta­tion at Rs 350 and super-spe­cial­ist con­sulta­tion at Rs 700, cla­ri­fied by an order of 13 Janu­ary 2026 that con­fines the Rs 700 to a re­cog­nised DM or MCh con­sulta­tion and caps in­pa­tient con­sulta­tions at two a day per spe­cial­ist. Where op­er­at­ors dis­close real­isa­tion it is more use­ful than any list price: Dr Lal PathLabs re­por­ted rev­enue per pa­tient of Rs 976 in the quarter to Septem­ber 2026, up from Rs 889, at 3.09 tests per pa­tient.

Indian Digital HealthVolge Quarterly25 •
The one number a buyer most needs, the enterprise contract price, is the one number nobody in the market publishes.

Three costs can­not be priced at all from pub­lic sources, and each is routinely as­ser­ted: in­surer and ad­min­is­trator cost per claim, the NHCX trans­ac­tion cost, and PM-JAY ad­min­is­trat­ive cost per claim. The only per-claim fig­ure in cir­cu­la­tion is the in­cent­ive pay­able under the Di­gital Health In­cent­ive Scheme, a pay­ment to a hos­pital and not a pro­cessing cost, and sev­eral vendor blogs con­flate the two. What can be cited is the prob­lem rather than the price: the ap­prox­im­ately 45-day av­er­age claim set­tle­ment cycle re­cor­ded in the July 2026 journal paper is what the claims ex­change is meant to com­press. A buyer should treat every cost-per-claim sav­ing quoted to it as un­evid­enced until the vendor pro­duces the baseline.

Teleconsultation at scale, and what the numbers do not say

eSanjeevani has recorded 50 crore consultations, which makes it the largest public teleconsultation service anywhere. What is published is a cumulative total and a current daily range, and from those two numbers no trend can be derived.

The pub­lic tele­con­sulta­tion fig­ure is genu­ine, large and al­most use­less for fore­cast­ing. A gov­ern­ment re­lease of 6 Oc­to­ber 2026 re­cords that eSanjeevani crossed 50 crore con­sulta­tions on 15 Septem­ber 2026, at 50,00,92,730 cu­mu­lat­ive tele­con­sulta­tions across all 36 states and union ter­rit­or­ies. That es­tab­lishes ca­pa­city bey­ond ar­gu­ment. What it does not es­tab­lish is dir­ec­tion, be­cause the gov­ern­ment pub­lishes a cu­mu­lat­ive total and a cur­rent daily range and noth­ing in between: no monthly series, no an­nual series, no state-by-state time series. A reader can there­fore say with con­fid­ence that the ser­vice is very large, and can­not say whether it is grow­ing, flat or de­clin­ing. Any­one who as­serts the third op­tion is in­fer­ring, and this chapter sets out why the in­fer­ence should not be made in pub­lic.

The pub­lished net­work is sub­stan­tial. The same re­lease re­cords more than 1.42 lakh Ay­ush­man Arogya Mandir spokes, 19,473 med­ical hubs, 901 on­line out­pa­tient de­part­ments, 2,41,923 re­gistered pro­viders and ser­vice in 15 lan­guages, with ar­ti­fi­cial in­tel­li­gence clin­ical de­cision sup­port in­teg­rated. The sys­tem was built by C-DAC Mo­hali. The op­er­at­ing rate is given as

ap­prox­im­ately 2.5 to 3 lakh con­sulta­tions a day, with a peak single day of 6,30,315. On util­isa­tion, women ac­count for 57.14 per cent of con­sulta­tions and 16.25 per cent of users are aged 60 and over, which is a demo­graphic pro­file no private plat­form has pub­lished and which is it­self the strongest evid­ence that the ser­vice reaches pop­u­la­tions com­mer­cial telemedi­cine does not.

The arith­metic prob­lem is simple and worth stat­ing plainly, be­cause it re­curs in every mar­ket re­port that quotes this fig­ure. A cu­mu­lat­ive total is the in­teg­ral of a flow that has been run­ning since 2019. A cur­rent daily range is an in­stant­an­eous read­ing. Di­vid­ing the first by elapsed time yields an av­er­age that ne­ces­sar­ily un­der­states re­cent years if the ser­vice grew and over­states them if it de­clined, and com­par­ing that av­er­age with the cur­rent daily range tells a reader only that the two are not identical. Without at least one in­ter­me­di­ate dated total, no growth rate can be com­puted. A plat­eau is con­sist­ent with the pub­lished num­bers; so is con­tin­ued growth; and neither has been pub­lished.

The out­pa­tient versus hub-and-spoke split is not in the 6 Oc­to­ber 2026 re­lease and could not be sourced else­where. The dis­tinc­tion is com­mer­cially sig­ni­fic­ant, since a fa­cil­ity-me­di­ated con­sulta­tion at a health and well­ness centre and a dir­ect cit­izen con­sulta­tion through an on­line out­pa­tient de­part­ment have dif­fer­ent cost struc­tures, dif­fer­ent clin­ical scope and dif­fer­ent im­plic­a­tions for a hos­pital group's re­fer­ral flow. The mix is there­fore un­known.

Unit eco­nom­ics are also un­avail­able. eSanjeevani is free to the cit­izen, and its cost per con­sulta­tion is not pub­lic. More than Rs 100 crore was al­loc­ated to the ser­vice in FY2020-21, ac­cord­ing to a par­lia­ment­ary reply re­por­ted in Septem­ber 2020, but di­vid­ing an early-year al­loc­a­tion by a cu­mu­lat­ive total ac­cu­mu­lated over six sub­sequent years would fab­ric­ate a unit cost rather than com­pute one. That cal­cu­la­tion ap­pears in cir­cu­la­tion and should be re­fused. What can be said is that the state has demon­strated will­ing­ness to fund tele­con­sulta­tion at no charge to the pa­tient, which sets the ref­er­ence price any com­mer­cial ser­vice com­petes against in the pub­lic-fa­cing seg­ment.

The private side is darker still

Private tele­con­sulta­tion volumes in India are ef­fect­ively not pub­lic. Neither Apollo 24|7 nor Practo has pub­lished plat­form-level con­sulta­tion counts in re­cent years. What is pub­lished is list pri­cing: Apollo 24|7 starts at Rs 200, Practo starts at Rs 199 with con­cern-spe­cific list­ings run­ning up to Rs 849, and Tata 1mg is quoted at Rs 199 to Rs 799 on third-party com­par­ison pages only. Con­tract rates for cor­por­ate or in­surer-fun­ded tele­con­sulta­tion are not pub­lished by any­one. The con­sequence is that the private mar­ket can­not be sized from the volume side or the value side, and that

Indian Digital HealthVolge Quarterly26 •

any mar­ket-size fig­ure for In­dian tele­con­sulta­tion is con­struc­ted rather than ob­served.

The reg­u­lat­ory frame has not kept pace with the volume, which is its own find­ing. Fifty crore con­sulta­tions have been de­livered under prac­tice guidelines dated 25 March 2020, is­sued as an ap­pendix to con­duct reg­u­la­tions of 2002. The suc­cessor in­stru­ment, the Na­tional Med­ical Com­mis­sion's con­duct reg­u­la­tions no­ti­fied on 2 Au­gust 2023, was held in abey­ance three weeks later and no re­place­ment has been is­sued. India there­fore runs the largest pub­lic tele­con­sulta­tion pro­gramme in the world on an in­stru­ment draf­ted in the first month of the pan­demic.

eSanjeevani, publishedFigure
Cumulative teleconsultations at 15 September 202650,00,92,730
CoverageAll 36 states and union territories
Spokes, hubs, online outpatient departments1.42 lakh and more, 19,473, 901
Registered providers2,41,923
Current daily rangeAbout 2.5 to 3 lakh
Peak single day6,30,315
Women as a share of utilisation57.14 per cent
Users aged 60 and over16.25 per cent
Monthly or annual seriesNot published
Cost per consultationNot public

One ad­ja­cent claim is worth ex­amin­ing be­cause it is the one most often used to jus­tify di­gital in­vest­ment at the front desk. A study by IIHMR, cited in the gov­ern­ment back­grounder of 6 July 2026, re­ports that Scan and Share re­duced wait­ing times from about one hour to between two and five minutes, against 23.21 crore tokens gen­er­ated as at 18 June 2026. The study it­self could not be loc­ated. Set against it, the July 2026 journal paper re­cords a counter-find­ing: con­ges­tion is re­dis­trib­uted to spe­cial­ist re­fer­ral desks rather than elim­in­ated. Both can be true. A re­gis­tra­tion queue can be dis­solved while the bot­tle­neck moves down­stream, and a buyer eval­u­at­ing a queue-man­age­ment in­vest­ment should ask which of the two out­comes the vendor is meas­ur­ing.

A cumulative total and a daily range establish capacity. They cannot establish direction, and the direction is what a buyer is buying.

The takeaway is a re­port­ing de­mand rather than a con­clu­sion. The gov­ern­ment has built and op­er­ates the largest pub­lic tele­con­sulta­tion ser­vice in the world, and it pub­lishes the two num­bers least use­ful for plan­ning around it. What a hos­pital group, a state de­part­ment or an in­surer needs be­fore com­mit­ting ca­pa­city is the monthly series, the out­pa­tient versus spoke split, the re­peat-con­sulta­tion rate and the re­fer­ral con­ver­sion rate into phys­ical care. None of those is pub­lished. Until they are, the hon­est po­s­i­tion is that tele­con­sulta­tion in India has demon­strated scale and has not demon­strated a trend, and any pro­jec­tion built on the 50 crore fig­ure is a pro­jec­tion built on one point.

The Gulf comparison

The Gulf states attached health data connection to licensing and claim submission. India did not. India nonetheless linked more than a billion records at a health spend per head under one twentieth of the Gulf's.

The single dif­fer­ence between Gulf health data ex­change and In­dian health data ex­change is not tech­no­logy, fund­ing or am­bi­tion: it is that con­nec­tion in the Gulf is a con­di­tion of being al­lowed to op­er­ate and be paid, and in India it is vol­un­tary. In Abu Dhabi a fa­cil­ity that does not con­nect to Malaffi can­not renew its De­part­ment of Health li­cence, and a fa­cil­ity with a Daman agree­ment can­not sub­mit claims until the con­nec­tion is com­plete. In Dubai, con­nec­tion to Na­bidh is a Dubai Health Au­thor­ity li­cence con­di­tion. The In­dian mis­sion's equi­val­ent pub­lished fig­ure is more than 450 vol­un­tary in­teg­ra­tions with no li­cens­ing con­sequence of any kind. The out­comes fol­low the in­cent­ives, and so does the cost, which runs in India's fa­vour.

Malaffi is a De­part­ment of Health ini­ti­at­ive op­er­ated by Abu Dhabi Health Data Ser­vices, a part­ner­ship between the De­part­ment and In­jazat now within M42. It went live at the end of July 2019, six months after the Orion Health con­tract, and by 14 Au­gust 2025 held 3.5 bil­lion clin­ical re­cords and 12.7 mil­lion unique pa­tient pro­files. The De­part­ment an­nounced in Septem­ber 2024 that all Abu Dhabi fa­cil­it­ies were con­nec­ted; LOINC ad­op­tion was re­por­ted at 90 per cent on 27 Oc­to­ber 2026. Con­nec­tion re­quires an Ac­ces­sion Agree­ment, a Malaffi se­cur­ity as­sess­ment, an HL7-cap­able elec­tronic med­ical re­cord and an Et­is­alat SD-WAN link.

Na­bidh in Dubai had ex­ceeded 10.41 mil­lion re­cords by the end of June 2025, across 1,888 li­censed fa­cil­it­ies, 53,659 pro­fes­sion­als and 91 con­nec­ted elec­tronic

Indian Digital HealthVolge Quarterly27 •

med­ical re­cord sys­tems. Under the Au­thor­ity's stand­ard DHA/HISHD/ST-09, fa­cil­ity up­load does not re­quire pa­tient con­sent and pa­tients may opt out, the mir­ror image of the In­dian con­sent ar­chi­tec­ture. The pen­alty range of AED 500 to AED 500,000 quoted in com­ment­ary traces only to vendor and law-firm blogs; the pub­lished levers are warn­ing let­ters, com­pli­ance or­ders and li­cence non-re­newal.

Riay­ati, op­er­ated by the Min­istry of Health and Pre­ven­tion, shows that the Gulf is not im­mune to the re­port­ing prob­lems de­scribed else­where in this edi­tion. Its dash­board, last up­dated Oc­to­ber 2024, gives 4.00 bil­lion con­nec­ted re­cords, 14 mil­lion unique pa­tients, 116,071 clini­cians and 4,952 fa­cil­it­ies, while the nar­rat­ive on the same page refers to more than 3,000 fa­cil­it­ies. What is sub­stant­ive is that Riay­ati is in­teg­rated with Na­bidh, Malaffi and the fed­eral iden­tity au­thor­ity, the nearest pub­lished iden­tity link in this com­par­ison and the thing India's vol­un­tary, con­sent-based ABHA does not have.

Saudi Ar­a­bia's NPHIES is the most in­struct­ive case for an in­surer or a hos­pital fin­ance func­tion, be­cause it is a claims plat­form rather than a re­cord ex­change, and its im­ple­ment­a­tion guide, gen­er­ated on 3 Decem­ber 2025, is pub­lished. As at Oc­to­ber 2025 the Coun­cil of Health In­sur­ance reg­u­lated 6,600 pro­vider or­gan­isa­tions, 28 in­surers and 8 third-party ad­min­is­trat­ors, serving about 14.1 mil­lion be­ne­fi­ciar­ies. On­board­ing stood at more than 6,419 pro­vider fa­cil­it­ies, 25 in­surers and more than 60 soft­ware vendors, with claims mar­ket share of 98 per cent and au­thor­isa­tion ad­ju­dic­ated within 30 minutes in 96 per cent of cases. Trans­ac­tion volumes were 143 mil­lion in 2023 and 292 mil­lion in 2024, with 96 mil­lion in the first quarter of 2025 alone.

Two points about NPHIES are usu­ally mis­re­por­ted. It runs FHIR R4 through a cent­ral­ised val­id­at­ing gate­way with no peer-to-peer ex­change, and it does not de­term­ine fraud: it flags sus­pi­cious trans­ac­tions for pay­ers and does not ad­ju­dic­ate. Fraud-re­duc­tion fig­ures, plat­form cost and fund­ing model are not pub­lic, and no on­board­ing dead­line for 2026 to 2028 has been pub­lished.

The Saudi cit­izen chan­nel fig­ures re­quire care. Se­h­haty passed 31 mil­lion users in 2025, but peer-re­viewed Min­istry of Health data show min­istry telemedi­cine con­sulta­tions rising from about 3.1 mil­lion in 2019 to 8.8 mil­lion in 2021 and then fall­ing to 4.3 mil­lion in 2023, with the 937 ser­vice car­ry­ing 86.1 per cent and Se­h­haty 11.53 per cent. The cir­cu­lat­ing fig­ure of 51 mil­lion vir­tual con­sulta­tions is not sourced to the min­istry. The Guin­ness World Re­cords re­cog­ni­tion of Seha Vir­tual Hos­pital, an­nounced 21 Oc­to­ber 2024, is an award an­nounce­ment and not an audited ca­pa­city meas­ure.

The spend com­par­ison should re­frame the dis­cus­sion. On WHO Global Health Ex­pendit­ure Data­base fig­ures for 2023, cur­rent health ex­pendit­ure per cap­ita in

cur­rent US dol­lars was USD 2,401.52 in the UAE, USD 1,825.25 in Saudi Ar­a­bia, USD 1,804.35 in Qatar and USD 84.69 in India: the UAE spends roughly 28 times what India spends per head. Against that, India had linked more than 100 crore re­cords to ABHA as at 22 May 2026, doubled from 50 crore in Feb­ru­ary 2025, against 97.6 to 97.8 crore iden­ti­fi­ers is­sued. No Gulf sys­tem has at­temp­ted link­age at that scale.

Five contrasts, each with a published figure

DimensionGulf positionIndian position
ConnectionLicence renewal and claim submission blocked without itVoluntary, more than 450 integrations, no consequence
IdentityRiayati integrated with the federal identity authorityABHA voluntary and consent-based
Records per headAbu Dhabi: 3.5 billion records, 12.7 million patientsOver 100 crore records against 97.6 to 97.8 crore ABHA
PayerSaudi gateway carries 98 per cent of claims; UAE cover mandatory in all seven emirates from 1 January 2025Mixed: PM-JAY, private insurance, large out-of-pocket spending
Spend per head, WHO 2023UAE USD 2,401.52; Saudi Arabia USD 1,825.25; Qatar USD 1,804.35India USD 84.69

The Gulf is also ahead on data law, which is the dir­ec­tion the In­dian ob­lig­a­tions of 13 May 2027 fol­low. Oman's law be­came fully en­force­able on 5 Feb­ru­ary 2026, with pen­al­ties up to OMR 500,000. Saudi Ar­a­bia's has been in force since 14 Septem­ber 2023 with en­force­ment from 14 Septem­ber 2024, treats health data as sens­it­ive and re­quires breach no­ti­fic­a­tion within 72 hours. UAE ex­ec­ut­ive reg­u­la­tions were un­is­sued as at Oc­to­ber 2026, but health data is ex­cluded from the fed­eral data law in any case: the op­er­at­ive re­gime is Fed­eral Law No. 2 of 2019, whose Art­icle 13 bars stor­ing, pro­cessing or trans­fer­ring UAE health data off­shore without health-au­thor­ity ap­proval, in force from 16 May 2021.

The Gulf bought near-universal connection with licensing power. India bought a billion links with per-capita spend of USD 84.69.
Indian Digital HealthVolge Quarterly28 •

Each sys­tem shows the other some­thing, and both state­ments are fac­tual rather than rhet­or­ical. The Gulf demon­strates that near-uni­ver­sal con­nec­tion is achiev­able within a few years when it is at­tached to li­cens­ing and claim sub­mis­sion, a lever India has not used na­tion­ally and could. India demon­strates that a bil­lion re­cord links can be as­sembled at a frac­tion of the per-head ex­pendit­ure, at a scale no Gulf state has at­temp­ted. For a buyer op­er­at­ing across both, a Gulf fa­cil­ity's con­nectiv­ity can be as­sumed from its li­cence while an In­dian fa­cil­ity's must be veri­fied. No pub­lished cost ex­ists for Malaffi, Na­bidh, Riay­ati or NPHIES, so no claim about what man­dated con­nec­tion would cost India can be sup­por­ted.

Three numbers to stop quoting

Three figures circulate widely in Indian digital health and not one can be traced to a primary source. Each has a defensible replacement, and in each case the replacement is weaker, which is the point.

The three most-quoted stat­ist­ics in In­dian di­gital health can­not be sourced. One is a PM-JAY ad­mis­sions and value fig­ure that ap­pears only on ag­greg­ator sites and con­tra­dicts the of­fi­cial count; one is a pending-dues fig­ure that is al­most cer­tainly a meas­ure of claims pro­cessed rather than claims un­paid; and one is an elec­tronic med­ical re­cord pen­et­ra­tion fig­ure at­trib­uted to a gov­ern­ment body that ap­pears never to have pub­lished it. All three are dir­ec­tion­ally plaus­ible, which is why they sur­vive, and all three are re­peated most often by parties with an in­terest in the dir­ec­tion they point. What fol­lows traces each to its ori­gin and states the de­fens­ible al­tern­at­ive, which in every case is a smal­ler claim or an ad­mis­sion that no fig­ure ex­ists.

One: 13.25 crore admissions worth Rs 2.03 lakh crore

The claim, usu­ally dated Septem­ber 2026 and ex­ten­ded to more than 38,000 hos­pit­als, ap­pears only on ag­greg­ator sites. It can­not be traced to any gov­ern­ment re­lease or to the Na­tional Health Au­thor­ity, and it is in­con­sist­ent with the of­fi­cial count pub­lished seven months earlier. The au­thor­ity's own po­s­i­tion as at 28 Feb­ru­ary 2026, re­layed through a gov­ern­ment re­lease of 23 March 2026, was 11.69 crore ad­mis­sions au­thor­ised across 36,229 em­pan­elled hos­pit­als. An in­crease of 1.56 crore ad­mis­sions in seven months is not im­possible, but it is un­veri­fied, and the rupee value has no coun­ter­part in any of­fi­cial state­ment.

The de­fens­ible state­ment is the of­fi­cial one, with its date at­tached: 11.69 crore ad­mis­sions au­thor­ised, of

which 6.74 crore in private hos­pit­als, across 36,229 em­pan­elled hos­pit­als, 19,483 pub­lic and 16,746 private, as at 28 Feb­ru­ary 2026. No cu­mu­lat­ive rupee value of au­thor­ised claims should be as­ser­ted, be­cause none has been pub­lished on a trace­able basis.

Two: Rs 1.21 lakh crore pending dues

This fig­ure, usu­ally given across 63,89,517 claims and at­trib­uted to a reply to a right-to-in­form­a­tion re­quest made to the Na­tional Health Au­thor­ity, is the most con­sequen­tial of the three, be­cause it is quoted in sup­port of the pro­pos­i­tion that the scheme is close to in­solv­ent on its ob­lig­a­tions. The un­der­ly­ing reply has not been ob­tained. The fig­ure is close to the whole scheme's cu­mu­lat­ive au­thor­ised value, which makes it al­most cer­tainly a meas­ure of total claims pro­cessed rather than of un­paid dues. A cu­mu­lat­ive pro­cessed value and an out­stand­ing pay­able dif­fer by or­ders of mag­nitude, and that con­fla­tion is the error.

The de­fens­ible state­ment is that no of­fi­cial fig­ure for un­paid PM-JAY dues ex­ists at any level. What can be cited, with sources and dates, is nar­rower and more cred­ible: roughly Rs 1,200 crore pending bey­ond six months in Hary­ana, re­por­ted by Tribune India around the sus­pen­sion of new ad­mis­sions by about 650 private hos­pit­als on 1 and 2 Septem­ber 2026; no­tices is­sued by the Pun­jab and Hary­ana High Court in 2026 over per­sist­ent and sys­temic delays; an order of the Hi­machal Pra­desh High Court re­quir­ing re­lease within three weeks; and the Comp­troller and Aud­itor Gen­eral's per­form­ance audit tabled in Au­gust 2023, which found 39.57 lakh claims pro­cessed bey­ond the 12-hour pre-au­thor­isa­tion win­dow. Those four make the ar­gu­ment the un­sourced fig­ure was being used to make, and they can be de­fen­ded.

Three: fewer than 15 per cent of Indian hospitals have an EMR

This stat­istic, usu­ally rendered as fewer than 15 per cent of In­dian hos­pit­als hav­ing fully di­git­ised med­ical re­cords and at­trib­uted to NITI Aayog in 2024, ap­pears in a vendor blog. No cor­res­pond­ing NITI Aayog doc­u­ment ex­ists that could be found, and the fig­ure could not be loc­ated in any NITI pub­lic­a­tion. Two re­lated arte­facts show how badly this corner of the lit­er­at­ure is con­tam­in­ated. A paper on a pre­print re­pos­it­ory claims that 76 per cent of In­dian hos­pit­als had ad­op­ted elec­tronic health re­cord sys­tems in 2014, cit­ing NITI Aayog; that is im­plaus­ible on its face and is al­most cer­tainly a mis-tran­scribed United States fig­ure. A widely

Indian Digital HealthVolge Quarterly29 •

cir­cu­lated split of 9 per cent rural against 60 per cent urban has no iden­ti­fi­able ori­gin whatever.

The de­fens­ible state­ment re­quires a proxy and an ad­mis­sion. There is no au­thor­it­at­ive, primary, cur­rent fig­ure for the share of In­dian hos­pit­als run­ning an elec­tronic med­ical re­cord, and say­ing so is the hon­est an­swer. The only us­able proxy is the pair pub­lished by the di­gital mis­sion in July 2026: 2.72 lakh of 5.33 lakh re­gistered fa­cil­it­ies were using mis­sion-en­abled soft­ware, set against roughly 1.4 mil­lion and more health es­tab­lish­ments na­tion­ally. Both halves of that proxy need their caveats stated, namely that re­gistry entries are self-de­clared and un­veri­fied, and that using en­abled soft­ware is not the same as main­tain­ing a re­cord.

The number in circulationWhat it traces toThe defensible statement
13.25 crore admissions worth Rs 2.03 lakh crore, 38,000+ hospitalsAggregator sites only; inconsistent with the official February 2026 count11.69 crore admissions authorised across 36,229 empanelled hospitals, 28 February 2026
Rs 1.21 lakh crore pending across 63,89,517 claimsAn unobtained right-to-information reply; close to cumulative authorised value, so probably claims processedNo official unpaid-dues figure exists; cite the Haryana Rs 1,200 crore, the two High Court matters and the 2023 CAG audit
Fewer than 15 per cent of Indian hospitals have an EMRA vendor blog attributing it to NITI Aayog; no such document foundNo primary figure exists; the only proxy is 2.72 lakh of 5.33 lakh registered facilities on enabled software, July 2026

A fourth error of the same fam­ily travels in com­ment­ary rather than in num­bers. There is a Comp­troller and Aud­itor Gen­eral per­form­ance audit of AB-PMJAY; there is no such audit of the di­gital mis­sion, and sev­eral com­ment­ar­ies con­flate the two. The Par­lia­ment­ary Stand­ing Com­mit­tee's 144th Re­port of March 2023 cri­ti­cised PM-ABHIM, the health in­fra­struc­ture mis­sion, for spend­ing about 20 per cent of its budget es­tim­ates; it did not cri­ti­cise the di­gital mis­sion.

The defensible version of each of these three numbers is smaller, narrower or an admission that nothing has been published. That is what a sourced position costs.

Four tests dis­pose of most of what cir­cu­lates in this field, and they can be ap­plied in the time it takes to read a slide.

  • Name the pub­lisher and the date. If the only at­tri­bu­tion is to a body rather than to a doc­u­ment of that body, treat the fig­ure as un­sourced.
  • Check the fig­ure against the nearest of­fi­cial count on the nearest date. The 13.25 crore claim fails this test on its own.
  • Ask what is being coun­ted. Claims pro­cessed, claims au­thor­ised, claims settled and claims out­stand­ing are four quant­it­ies, and a fig­ure that fits one of them is not evid­ence for an­other.
  • Ask who be­ne­fits from the dir­ec­tion. A low pen­et­ra­tion stat­istic sells soft­ware; a high ad­op­tion stat­istic de­fends a pro­gramme; neither in­terest makes the num­ber wrong, and both make veri­fic­a­tion ne­ces­sary.

The wider re­gister of what is not avail­able should be read along­side those tests. There is no primary In­dian health-tech fund­ing series. The CAG re­port num­ber could not be con­firmed. No health be­ne­fit pack­age re­vi­sion after 2022 was loc­ated, and no mile­stone three fig­ure has been pub­lished. No in­surer, ad­min­is­trator, au­thor­ity or claims-ex­change cost per claim ex­ists in pub­lic. The eSanjeevani out­pa­tient split, the in­cent­ive scheme's rate table and ex­piry date, tender val­ues for every state ex­cept Assam and Ker­ala, Met­ro­polis FY2026, private tele­con­sulta­tion volumes, the pub­lished cost of any Gulf plat­form, and whether any Sig­ni­fic­ant Data Fi­du­ciary has been des­ig­nated are all un­avail­able. No order im­pos­ing a pen­alty under the data pro­tec­tion law has been found, and none pen­al­ising an in­surer for a missed health turn­around time. The cred­ib­il­ity of a buyer's po­s­i­tion rests on say­ing so.

Indian Digital HealthVolge Quarterly30 •

The year ahead: the Calls

A Call is a prediction written to be graded: falsifiable, dated, and confidence-rated. Ten for the year. The 2028 edition will mark each one hit, miss or partial.

How the Calls are made and graded

A forward-look that refuses to mark its own homework is just a brochure. Volge Quarterly makes a small number of Calls and grades them in the open the following year.

The five rules of a Call

Falsifi­able. A Call states some­thing that can be shown true or false by a named date: no un­score­able trend-talk. Dated. Every Call car­ries the year it re­solves; here, the end of 2027. Con­fid­ence-rated. High, Me­dium or Low, so a con­trarian low-con­fid­ence Call and a high-con­fid­ence base case are scored fairly. Sourced. The reas­on­ing cites the sec­tor evid­ence the Call rests on. Few, not many. Ten sharp Calls build a re­cord; a page of forty hedged pre­dic­tions grades to noise.

The confidence bands, read plainly

BandWhat it meansHow to weight it
HighThe base case; the evidence points one wayTreat as the planning assumption
MediumLikely, but with a real path to being wrongHold, but hedge
Medium–HighStronger than even, short of a base caseLean in, watch the swing factor
LowA contrarian or early Call, placed deliberatelyWatch; do not yet build on it

The 2028 edi­tion opens with the Score­card: each Call marked hit, miss or par­tial, with a run­ning hit-rate by band.

The Calls: 2027, at a glance

Ten dated, falsifiable predictions for the year. Confidence is stated so a contrarian low-confidence Call and a high-confidence base case are read, and scored, differently.

  • Call 1: Prof­it­ab­il­ity at scale ar­rives, Me­dium, Re­solves 2027
  • Call 2: The cheap chan­nels win the growth, Me­dium–High, Re­solves 2027
  • Call 3: Fund­ing rises but con­cen­trates, Me­dium, Re­solves 2027
  • Call 4: The AI scribe be­comes table stakes, High, Re­solves 2027
  • Call 5: DPDP turns into a deal gate, Me­dium, Re­solves 2027
  • Call 6: The IPO test, de­ferred not denied, Me­dium, Re­solves 2027
  • Call 7: The e-phar­macy va­cuum per­sists, Me­dium–High, Re­solves 2027
  • Call 8: In­sur­tech is the fast­est-grow­ing seg­ment, Me­dium–High, Re­solves 2027
  • Call 9: Con­sol­id­a­tion claims the tail, Me­dium, Re­solves 2027
  • Call 10: The ABDM trans­ac­tional turn be­gins, Low, Re­solves 2027

Each Call draws on the sec­tor data in Part I and on Volge's Rules of the Game reg­u­lat­ory tracker. Source ma­ter­ial: Volge's in­ternal sec­tor play­book . No Score­card in Vol. I: the 2028 edi­tion grades these.

Calls one to three

1. Profitability at scale arrives

At least one In­dian di­gital-health plat­form reaches sus­tained op­er­at­ing prof­it­ab­il­ity at scale: a multi-seg­ment player post­ing pos­it­ive EBITDA for two con­sec­ut­ive quar­ters.

Con­fid­ence: Me­dium · Re­solves end-2027

Cap­ital has turned se­lect­ive and re­wards pos­it­ive unit eco­nom­ics; only plat­forms own­ing phar­macy, dia­gnostics and tele­con­sulta­tion to­gether have the life­time value to cross over, and the lead­ers are close.

2. The cheap channels win the growth

Pub­lic-rail and busi­ness-to-busi­ness or busi­ness-to-gov­ern­ment chan­nels drive the ma­jor­ity of net new di­gital-health rev­enue growth, ahead of dir­ect-to-con­sumer sub­scrip­tion.

Con­fid­ence: Me­dium–High · Re­solves end-2027

With ac­quis­i­tion cost struc­tur­ally above per-con­sult value, sur­vival runs through cor­por­ate, gov­ern­ment and in­fra­struc­ture chan­nels; 2027 is when that shift shows in the rev­enue mix.

3. Funding rises but concentrates

An­nual di­gital-health ven­ture fund­ing ex­ceeds its ~$0.70 bil­lion 2025 level and re­cov­ers past $1 bil­lion, while deal count stays below the 2021 peak: cap­ital con­cen­trat­ing in fewer, lar­ger, eco­nom­ics-proven rounds.

Con­fid­ence: Me­dium · Re­solves end-2027

Indian Digital HealthVolge Quarterly31 •

The 2024 re­bound to ~$1.13B across 112 deals did not hold: 2025 fell to about $0.70B across 54 deals (Inc42, 2026), and Tracxn re­cords about $626M across 114 rounds to Septem­ber 2026. The tra­ject­ory is up in value, down in count, as growth-at-any-cost loses fund­ing.

Calls four to six

4. The AI scribe becomes table stakes

AI scribes and dia­gnostic co­pi­lots are em­bed­ded in the ma­jor­ity of India's large tele­con­sulta­tion and hos­pital plat­forms, shift­ing cost-to-serve by cut­ting per-con­sulta­tion ef­fort.

Con­fid­ence: High · Re­solves end-2027

The tech­no­logy is ma­ture and the unit-eco­nom­ics pres­sure is ex­actly where it bites; clini­cian AI use already rose from ~12% to 41% in a year. The cheapest veri­fi­able Call in the set.

5. DPDP turns into a deal gate

The Di­gital Per­sonal Data Pro­tec­tion re­gime be­comes a gat­ing di­li­gence item for health data: at least one not­able di­gital-health round or ac­quis­i­tion turns on DPDP and health-data read­i­ness.

Con­fid­ence: Me­dium · Re­solves end-2027

The DPDP Rules were no­ti­fied on 13 Novem­ber 2025 (G.S.R. 846(E)); con­sent-man­ager re­gis­tra­tion opens on 13 Novem­ber 2026 and the sub­stant­ive ob­lig­a­tions com­mence on 13 May 2027, so the gate closes dur­ing the Call's win­dow. Health data is the most sens­it­ive cat­egory, so it is where com­pli­ance first be­comes a price of entry rather than a check­box.

6. The IPO test, deferred not denied

The first cred­ible pure-play di­gital-health pub­lic list­ing (API Hold­ings / PharmEasy the bell­wether) either lists on demon­strated cash-flow pos­it­iv­ity or slips again, but no profit­less plat­form clears the pub­lic mar­ket.

Con­fid­ence: Me­dium · Re­solves end-2027

API Hold­ings filed for up to ₹6,250 crore, with­drew in the cor­rec­tion, and a re­vival is con­di­tional on turn­ing cash-flow pos­it­ive; the pub­lic mar­ket gates on the same prof­it­ab­il­ity test as the private rounds.

The rules have sat un-no­ti­fied since 2018 des­pite a 2023 Delhi High Court dir­ec­tion; in­sti­tu­tional in­er­tia and con­tested in­terests make status quo the base case, and valu­ations keep their reg­u­lat­ory dis­count.

Con­fid­ence: Me­dium–High · Re­solves end-2027

Calls seven and eight

7. The e-pharmacy vacuum persists

The e-phar­macy draft rules re­main un-no­ti­fied through 2027, and the seg­ment con­tin­ues to op­er­ate under off­line drug law: the single largest stand­ing policy risk, un­re­solved.

8. Insurtech is the fastest-growing segment

Health in­sur­tech re­mains the fast­est-grow­ing of the seven seg­ments, and health in­sur­ance holds its place as the largest non-life line (>40% of premium) as OPD and group cover deepen.

Con­fid­ence: Me­dium–High · Re­solves end-2027

Health over­took motor in FY25 at ~41% of non-life premium; group and out-pa­tient cover are the struc­tural growth vec­tors, and they are ex­actly the payer wedge di­gital health needs.

Calls nine and ten

9. Consolidation claims the tail

Between a fifth and a third of the ~11,000-firm base fails or is ab­sorbed over the cycle, and the con­glom­er­ates (Tata, Re­li­ance, the Manipal group) re­main the de­fin­ing ac­quirers.

Con­fid­ence: Me­dium · Re­solves end-2027

~90% of the base is sub-scale; a dis­cip­lined cap­ital mar­ket starves single-seg­ment play­ers, and stra­tegic buy­ers provide the only re­li­able exit. The dir­ec­tion is not in ques­tion, only the pace.

10. The ABDM transactional turn begins

The Uni­fied Health In­ter­face, launched on 29 June 2026, reaches ma­ter­ial trans­ac­tion volume, with open dis­cov­ery-and-book­ing be­gin­ning to un­bundle the closed plat­forms: a struc­tural shift, not yet a dom­in­ant one.

Con­fid­ence: Low · Re­solves end-2027

The net­work launched on 29 June 2026 with four cit­izen ser­vices live (PIB), so the ar­chi­tec­ture is no longer pro­spect­ive and the Call now turns on volume rather than ex­ist­ence. Its ef­fects re­main nas­cent and de­pend on gov­ern­ment pace, and it is placed to be graded hon­estly either way.

The Calls · Volge Quarterly 2027

Indian Digital HealthVolge Quarterly32 •
Ten Calls, dated and confidence-rated. Twelve months on, anyone can mark them right or wrong without arguing about what was meant.

By domain, and three scenarios

The year read from four angles (the market, the technology, the rules and the capital) and then bracketed by a bull, a base and a bear case.

The market, the technology, the rules, the capital

Four short outlooks, each drawn from one of Volge's running series, triangulate the year.

The market: from State of Play

The sec­tor enters 2027 at roughly $15–18 bil­lion, scal­ing to­wards a $100 bil­lion-plus fig­ure by 2033 on severe care un­der­sup­ply: 1.1 doc­tors per 1,000 against 2.8 in de­veloped mar­kets. The bind­ing con­straint is unit eco­nom­ics, not reg­u­la­tion or cap­ital, and 2027 is the reck­on­ing: value con­cen­trates in the multi-seg­ment plat­forms and the re­cur­ring-rev­enue seg­ments, while the long tail of sub-scale firms thins.

The technology: from Voice of Volge

Gen­er­at­ive AI is the ho­ri­zontal of the year. Voice of Volge's Ap­plied AI thesis (that gov­ernance, not the model, gates value) lands cleanly in In­dian di­gital health: the mod­els are ready and frugal, and the work is con­sent, ac­cur­acy and li­ab­il­ity. The AI scribe moves from nov­elty to de­fault, and the cost to serve falls enough to make thin mar­gins sur­viv­able.

The rules: from Rules of the Game

The DPDP Rules, no­ti­fied 13 Novem­ber 2025 with sub­stant­ive du­ties from 13 May 2027, move com­pli­ance from over­head to gate as they apply to health data, and the e-phar­macy va­cuum per­sists as the largest stand­ing policy risk. The Rules of the Game tracker car­ries both as act­ive re­gimes; to­gether they de­cide which mod­els are fin­ance­able and which carry a reg­u­lat­ory dis­count.

The capital: from Field Notes

Fund­ing re­boun­ded to ~$1.13 bil­lion across 112 deals in 2024 and now re­wards proven eco­nom­ics over growth, with the con­glom­er­ates as the de­fin­ing

ac­quirers. The de­liv­ery proof (what ac­tu­ally ships and works in pro­duc­tion) will be car­ried in Field Notes as Volge's en­gage­ments are writ­ten up be­hind the sign-off gate.

Bull, base and bear: 2027

The Calls are the base case. Bracketing them with an optimistic and a pessimistic scenario shows what would have to be true for the year to break either way.

Bull: the inflection lands early

Two or more plat­forms cross into sus­tained prof­it­ab­il­ity; AB PM-JAY tele­con­sulta­tion re­im­burse­ment widens ma­ter­i­ally; the e-phar­macy rules are fi­nally no­ti­fied, re­mov­ing the dis­count; and a cred­ible IPO prints. Fund­ing steps up and ro­tates de­cis­ively into pro­vider soft­ware, chronic-care and in­sur­tech. The sec­tor exits 2027 with a proven profit tem­plate and a re-rat­ing of the re­cur­ring-rev­enue seg­ments.

Base: discipline without drama

The Calls hold. One plat­form reaches scale prof­it­ab­il­ity, the cheap chan­nels carry the growth, fund­ing rises but con­cen­trates, the AI scribe be­comes stand­ard, and the e-phar­macy va­cuum per­sists. Con­sol­id­a­tion thins the tail. The year is one of quiet re­pri­cing to­wards qual­ity rather than a break­out.

Bear: the squeeze overshoots

Cap­ital tight­ens fur­ther, the prof­it­ab­il­ity cross­ings slip, and a fund­ing air-pocket strands mid-stage firms with high ac­quis­i­tion costs and no payer. The e-phar­macy am­bi­gu­ity hardens into en­force­ment risk, and a DPDP pen­alty or data in­cid­ent chills en­ter­prise de­mand. At­tri­tion runs to the top of the 20–30% range, and the IPO win­dow stays shut. The op­por­tun­ity is in­tact; the timeline slips a cycle.

What to watch for the break

The swing factors are the same three: the pace of payer deep­en­ing (PM-JAY and group cover), the e-phar­macy no­ti­fic­a­tion, and whether one plat­form can print two clean prof­it­able quar­ters. Move any of the three and the year moves with it.

The opportunity is not in question. The timing is. 2027 decides whether the inflection lands now or slips a cycle.
Indian Digital HealthVolge Quarterly33 •

By do­main · Volge Quarterly 2027

What to watch, and the record

From the year's read to the year's action: what to do, what the rules demand, and the numbers and terms behind the narrative.

The operator's playbook: what to do with the year

Five moves follow directly from the Calls. They are written for the operator and the board, not the analyst.

1 · Own the denominator, not just the numerator

Stop op­tim­ising ac­quis­i­tion cost in isol­a­tion and re-en­gin­eer life­time value. Cross-sell into phar­macy and dia­gnostics, build the chronic-care re­la­tion­ship that re­curs, and treat every ac­quired cus­tomer as a multi-seg­ment an­nu­ity. The plat­forms that win in 2027 change the de­nom­in­ator of the LTV-to-CAC ratio.

2 · Move to where acquisition is free

Pri­or­it­ise cor­por­ate group health, gov­ern­ment volume and ABDM-nat­ive dis­tri­bu­tion over paid dir­ect-to-con­sumer. A user who ar­rives through an em­ployer at ₹300 and re­curs an­nu­ally re­pays in months; a user bought for ₹1,200 may never repay. Build for the chan­nel, not the app store.

3 · Make compliance a product

Treat DPDP and ABDM con­sent as fea­tures that win en­ter­prise and gov­ern­ment deals, not as a tax. The firms that can prove law­ful, per­mis­sioned data will clear di­li­gence the care­less can­not, and that be­comes a moat as the largest con­tracts move to the com­pli­ant.

4 · Earn the payer relationship

The wedge into the unit-eco­nom­ics prob­lem is the payer. Build the em­ployer and in­surer re­la­tion­ships, the OPD and group-cover rails, and the claims tech­no­logy: the as­sets that put someone other than the pa­tient on the other side of the trans­ac­tion.

5 · Deploy frugal AI against the labour constraint

Adopt the AI scribe and triage layer now: it is be­com­ing table stakes, it cuts cost to serve, and it stretches the scarce clini­cian. Po­s­i­tion it as gov­erned de­cision sup­port, keep a clini­cian in the loop, and hold the line on ac­cur­acy and li­ab­il­ity.

Regulatory annex: the segment crosswalk

The seven segments mapped to their governing instruments and the current state of each: the single reference for regulatory exposure by segment.

SegmentPrimary regulationStatus / risk
1 · TeleconsultationTelemedicine Practice Guidelines 2020; state councilsClear but state-fragmented; cross-state licensure friction
2 · E-pharmacyDraft e-pharmacy rules; Drugs & Cosmetics Act 1940Unsettled: rules never notified; highest policy risk
3 · E-diagnosticsNABL / ISO 15189; Clinical Establishments ActAccreditation-led; clear
4 · Provider softwareABDM standards; DPDP Act 2023Interoperability and data governance
5 · Chronic-care & RPMDPDP Act; device rules where hardware is involvedMixed; clear for software
6 · Wellness & preventiveConsumer-protection; advertising standardsLight-touch
7 · Insurtech & claimsIRDAI regulationsRegulated; established

Sources: MoHFW; CDSCO; DPDP Act 2023; IRDAI. Cur­rent to June 2026.

The regulatory timeline that matters for 2027

E-phar­macy no­ti­fic­a­tion: pending since 2018, court-dir­ec­ted since 2023; the single largest swing factor. DPDP Rules: op­er­a­tion­al­isa­tion for health data; con­sent, loc­al­isa­tion, de­le­tion; pen­al­ties to ₹250 crore. PM-JAY tele­con­sulta­tion re­im­burse­ment: ex­pan­sion bey­ond se­lect states would re-rate the seg­ment. IRDAI OPD and senior-cover meas­ures: the payer-deep­en­ing sig­nal to track.

Indian Digital HealthVolge Quarterly34 •

The data appendix: the sector in numbers

The quantitative picture in one place, on the reconciled basis used throughout. Ranges denote genuine source disagreement on scope.

Market & public rails

MetricValueBasis
Market size (2025)~$15–18BBroad digital-health scope
2033 projection$100B+~25% CAGR
Telehealth sub-market (2025)~$3.9B → ~$9.8B (2030)~20% CAGR (Mordor)
Startups~11,000~90% sub-scale
2025 funding~$0.70B / 54 dealsDown on 2024 (Inc42, 2026)
ABHA IDs issued93 crore+PIB, Jul 2026
Health records linked104 crore+PIB, Jul 2026
eSanjeevani consultations50.01 croreMoHFW, Sep 2026

Derived analytics

MetricValueBasis
Market-to-projection multiple~6×~$17B → $100B+ by 2033
Teleconsult CAC : consult value~2–6×₹800–2,000 CAC vs ₹300–800 value
Top-5 revenue concentration~60%Teleconsult & e-pharmacy
Sub-scale share of base~90%Pre-revenue or sub-₹1 cr
Expected attrition (2 yrs)20–30%Fail or be acquired
Healthtech VC to medtech/dx~30%Segment rotation
ABHA penetration~60%~85 cr of ~1.4B population
Health share of non-life insurance~41%Largest non-life segment (FY25)
Clinician AI adoption12% → 41%2024 → 2025

Methodology, sources & glossary

How this edition was built, what it draws on, and the terms it uses.

Methodology

Volge Quarterly syn­thes­ises Volge's run­ning in­tel­li­gence into a dated, falsifi­able read of the year. Mar­ket data is re­con­ciled across mul­tiple third-party sources; where they dis­agree on scope, a range is given rather than a single point es­tim­ate. Each Call is writ­ten to be falsifi­able, dated to a res­ol­u­tion year, and con­fid­ence-rated. The 2028 edi­tion will grade every Call hit, miss or par­tial, and re­port a run­ning hit-rate by con­fid­ence band.

Principal sources

Cus­tom Mar­ket In­sights and Mordor In­tel­li­gence (mar­ket siz­ing); Na­tional Health Au­thor­ity / ABDM dash­board (rails, Janu­ary 2026); Min­istry of Health & Fam­ily Wel­fare and Di­gital Health News (eSanjeevani, Novem­ber 2025); IRDAI (in­sur­ance); Tracxn, Inc42, En­trackr and com­pany fil­ings (fund­ing, rev­enue, deals, 2024–26); EY, PIB and Rest of World (gen­er­at­ive AI). Fig­ures cur­rent to June 2026. Un­der­ly­ing de­tail is held in Volge's in­ternal sec­tor play­book.

Glossary

ABDM: Ay­ush­man Bharat Di­gital Mis­sion; the na­tional health-iden­tity and in­ter­op­er­ab­il­ity layer. ABHA: Ay­ush­man Bharat Health Ac­count; the port­able health ID is­sued under ABDM. CAC / LTV: cus­tomer-ac­quis­i­tion cost; life­time value. Their ratio gov­erns sur­vival. eSanjeevani: the Gov­ern­ment's na­tional telemedi­cine ser­vice; the world's largest. DPDP: the Di­gital Per­sonal Data Pro­tec­tion Act 2023 and its Rules. UHI: Uni­fied Health In­ter­face; the open dis­cov­ery-and-book­ing net­work, the 'UPI for health'. SaMD: Soft­ware as a Med­ical Device; clin­ical AI reg­u­lated by CDSCO.

The risk register

Five risks recur across the sector. None is fatal individually; together they raise the bar on execution, and each has a known mitigation.

RiskMitigation
Crowded market with funded incumbentsFind a defensible niche; differentiate on execution, not idea
CAC exceeds LTV at scaleValidate unit economics early with cohort analysis; model scenarios before scaling
Regulatory change (telemedicine, e-pharmacy, data)Monitor developments; build a clinical and regulatory function; engage policy bodies early
Reimbursement dependenceDiversify revenue; keep a strong out-of-pocket baseline; avoid single-payer reliance
Trust & safety (quality, breaches)Rigorous provider vetting; security from day one; liability insurance; transparent incident response

The stand­ing risk re­gister for the sec­tor. Cur­rent to June 2026.

The through-line of the re­gister is that the sec­tor's risks are con­cen­trated not in the tech­no­logy but in the model: who pays, how the cus­tomer is ac­quired, and whether the reg­u­lat­ory ground is firm. A ven­ture that has answered those three ques­tions has re­tired most of the risk that ac­tu­ally kills di­gital-health busi­nesses.

Indian Digital HealthVolge Quarterly35 •

Talent, organisation and compliance

The core team needs four capabilities, and the compliance function is non-negotiable from the start.

The four capabilities

Health­care do­main ex­pert­ise in a founder or co-founder (clin­ical, op­er­a­tional or policy) for cred­ib­il­ity with pro­viders and reg­u­lat­ors. Tech­no­logy and product built mo­bile-first and for ABDM in­ter­op­er­ab­il­ity. Op­er­a­tions and growth that un­der­stand India's reg­u­lat­ory, re­im­burse­ment and dis­tri­bu­tion com­plex­ity. Fin­ance and com­pli­ance from day one, given data-pri­vacy and med­ical-re­gis­tra­tion ob­lig­a­tions.

Compliance essentials by segment

Tele­con­sulta­tion: doc­tors re­gistered in the rel­ev­ant state; Telemedi­cine Guidelines 2020 on con­sent, pre­scrip­tions and re­cords. E-phar­macy: a phar­macy li­cence to dis­pense; pre­scrip­tion veri­fic­a­tion; cold chain main­tained. Dia­gnostics: NABL or ISO 15189 ac­cred­it­a­tion; trained phle­bot­om­ists; clin­ical val­id­a­tion of re­ports. Clin­ical AI: CDSCO ap­proval where the soft­ware is a med­ical device; po­si­tioned as de­cision sup­port, not stan­dalone dia­gnosis. Data & ABDM: ex­pli­cit con­sent and de­le­tion rights under DPDP; data loc­al­isa­tion; pen­al­ties up to ₹250 crore.

The common mistakes

Hir­ing for scale be­fore the model is val­id­ated; skip­ping com­pli­ance hires; and build­ing product without clin­ical input. Each is avoid­able, and each is fatal often enough to be worth nam­ing.

2027, in one view

The edition compressed: where the sector stands, what moves it, and what to watch.

Where it stands

A ~$15–18 bil­lion mar­ket on a base of ~11,000 mostly sub-scale firms, built on severe care un­der­sup­ply and the ABDM pub­lic rails, gated by unit eco­nom­ics rather than cap­ital or reg­u­la­tion.

What moves it in 2027

The unit-eco­nom­ics reck­on­ing: growth stops being fun­ded; the mod­els that repay sur­vive. Dis­tri­bu­tion shifts to the free chan­nels: cor­por­ate, gov­ern­ment, ABDM. Com­pli­ance under DPDP be­comes a moat and a deal gate. The payer deep­ens (health in­sur­ance,

OPD and group cover), loosen­ing the CAC trap. Value mi­grates down the acu­ity curve to chronic-care, pro­vider soft­ware and in­fra­struc­ture. Frugal, sov­er­eign AI cuts the cost to serve and stretches the scarce clini­cian.

What to watch

The e-phar­macy no­ti­fic­a­tion, PM-JAY re­im­burse­ment ex­pan­sion, IRDAI moves on OPD and group cover, the first prof­it­able plat­form quarter, and the first cred­ible pure-play IPO. Move any of these and the year moves with it.

The bottom line

2027 does not de­cide whether In­dian di­gital health suc­ceeds: the struc­tural de­mand settles that. It de­cides who suc­ceeds, and on whose money. The win­ners are already vis­ible in their unit eco­nom­ics.

The watchlist

The signals to watch through the year: the seed of next year's Calls.

DPDP Rules en­force­ment timeline as it ap­plies to health data. ABDM trans­ac­tion volumes, not ac­count counts: the test of whether the rails carry real traffic. The e-phar­macy no­ti­fic­a­tion, pending since 2018 and court-dir­ec­ted since 2023. PM-JAY tele­con­sulta­tion re­im­burse­ment ex­pan­sion bey­ond se­lect states. IRDAI moves on out-pa­tient and group cover: the payer-deep­en­ing sig­nal. Clin­ical ac­cept­ance and any re­im­burse­ment of AI-scribe and dia­gnostic-co­pi­lot out­puts. The first cred­ible pure-play di­gital-health IPO, and whether it prints on cash-flow pos­it­iv­ity. Con­sol­id­a­tion pace among tele­con­sulta­tion play­ers as the unit-eco­nom­ics squeeze plays out.

Next year

The 2028 edi­tion opens with the Score­card: each of these ten Calls graded hit, miss or par­tial, with a run­ning hit-rate by con­fid­ence band. A for­ward-look that re­fuses to mark its own home­work is just a bro­chure; Volge Quarterly marks it.

Indian Digital HealthVolge Quarterly36 •
Indian Digital Health

The defensible version of each of these three numbers is smaller, narrower or an admission that nothing has been published. That is what a sourced position costs.

Version · VSP-OTG-005 · 2026
volgePublished
every quarter
About Volge Quarterly

Volge Quarterly is Volge's signature series, published every quarter for enterprise customers. Each edition takes one subject, sets out where it currently stands on the published record, and makes a set of dated, falsifiable judgements on where it is going, written to give a buyer something firmer than a forecast: every figure carries its source and its date, every judgement carries the date on which it resolves, and the following year's edition grades each one hit, missed or partial.

Where a figure is not published, the edition says so rather than estimating it. Where published sources disagree, both are given and the disagreement is stated rather than averaged away. A number that does not survive checking is corrected here rather than repeated.

The edition carries no recommendation of any supplier and no offer of service. Where a vendor, platform or deployment is named it is because it is part of the published record of the subject.

Terms of use

This edition may be shared freely. It may not be altered or republished without permission, and figures carry their stated basis and date. Names and marks appearing in it are the property of their respective owners.